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Nitric oxide (NO) is a lipophilic, freely-diffusing, reactive (free radical) gas that acts as 
a signalling molecule in the cardiovascular, nervous and immune systems. Since the discovery 
that NO acts as a powerful vasodilator, several clinically useful NO-donor drugs have been 
developed in cardiovascular medicine; for example, nitroglycerin and isosorbide dinitrate for 
the treatment of acute angina. However, all the drugs developed to date have been spontaneous 
NO donors that non-specifically release NO in physiological milieu, leading to systematic 
exposure of host tissues to NO.  Thus, there is an unmet opportunity to create innovative NO 
technologies that selectively target NO to specific tissue locations in the body. Antibody-
directed enzyme prodrug therapy (ADEPT) is one promising strategy that could enable such 
tissue-specific NO delivery. In ADEPT, an antibody or antibody fragment that recognises a 
tissue-specific antigen is linked to an enzyme capable of activating some prodrug. 
Administration of the antibody-enzyme bioconjugate localises the enzyme activity to the tissue 
site bound by the attached antibody and administration of the prodrug then leads to selective 
revelation of active drug at the tissue site. A major advantage of ADEPT is its ability to reduce 
unwanted side-effects. In this Masters research project, an new ADEPT strategy was explored 
that uses an antibody-β-lactamase bioconjugate in combination with a cephalosporin-3′-
diazeniumdiolate (C3D) NO-donor prodrug, a class of highly drug-like compounds that rapidly 
release NO upon reaction with β-lactamases, as a strategy for targeted NO therapy. 
A possible application for a targeted NO therapy of this type is as an emergency 
intervention during heart attacks caused by atherosclerotic plaques, where the plaque occludes 
a coronary vessel and causes myocardial ischemia. Patients suffering from this type of heart 
attack could be given ADEPT NO therapy by paramedics that triggers vasodilation directly at 
the site of the occlusion. The increased cardiac perfusion and reduced myocardial ischemia 
could preserve the cardiac tissue and buy time for patients to undergo emergency surgery to 
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remove the blockage. ADEPT under this scenario could use an atheroma-targeting antibody 
(e.g. antiLIBS scFv, Prof. Karlheinz Peter) β-lactamase conjugate in combination with a C3D. 
 My Masters project aimed to provide the first molecular proof-of-concept towards this 
goal by constructing a model antibody-β-lactamase conjugate and demonstrating that such a 
conjugate can cause NO release from a C3D. The specific aims were: 1) design, clone and 
express a suitable TEM-1 β-lactamase, 2) conjugate the TEM-1 β-lactamase to the model 
antibody fragment Fab' 528, 3) synthesise and purify a C3D (DEA-C3D 1) and 4) confirm NO 
release from DEA-C3D 1 is triggered by the Fab' 528-β-lactamase conjugate. 
The TEM-1 β-lactamase was cloned and expressed in good yield in E. coli cells and the 
protein was purified using an immobilised metal affinity chromatography/size exclusion 
chromatography sequence. The TEM-1 β-lactamase was successfully coupled to the thiol-
bearing antibody fragment Fab' 528 via a sulfo-SMCC linker to give a TEM-1 β-lactamase-
SMCC-Fab' 528 conjugate. A fresh sample of DEA-C3D 1 was then synthesised, purified and 
characterised using the previously reported methods. Importantly, NO measurements showed 
that the unconjugated TEM-1 β-lactamase and the TEM-1 β-lactamase-SMCC-Fab' 528 
conjugate both triggered NO release from DEA-C3D 1, although the conjugate showed lower 
activity. This study demonstrated for the first time that it is possible to produce a β-lactamase-
Fab' 528 conjugate that triggers NO release from C3Ds and opens the way for studies aimed at 






13C NMR   Carbon nuclear magnetic resonance spectroscopy 
1H NMR   Proton nuclear magnetic resonance spectroscopy 
ADEPT   Antibody directed enzyme prodrug therapy 
C3D    Cephalosporin-3'-diazeniumdiolates 
cGMP    Cyclic guanosine monophosphate 
CPG2    Carboxypeptidase G2 
CSIRO   Commonwealth scientific and industrial research organisation 
Da    Daltons 
DEA    Diethylamine 
DNA    Deoxyribonucleic acid 
DSF    Differential scanning fluorimetry 
DTT    Dithiothreitol  
EDRF    Endothelial derived relaxing factor 
EDTA    Ethylenediaminetetraacetic acid 
EGFR    Epidermal growth factor receptor 
ESBL    Extended spectrum β-lactamase 
eNOS    Endothelial nitric oxide synthase 
GFC    Gel filtration chromatography 
GSH    Glutathione (reduced form) 
GST    Glutathione-S-transferase 
GTG    GoTaq® Green 
HRP    Horseradish peroxidase 
IAESTE International association for the exchange of students for 
technical experience 
IMAC    Immobilised metal affinity chromatography 
iNOS    inducible nitric oxide synthase 
IPTG    Isopropyl β-D-1-thiogalactopyranoside 
MALDI- TOF   Matrix-assisted laser desorption/ionization-time of flight  
    mass spectrometry 
m/z    Mass to charge ratio 
NHS    N-hydroxysuccinimide 
nNOS     Neuronal nitric oxide synthase 
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NONOates   Diazeniumdiolates 
NOS    Nitric oxide synthase 
PBPs    Penicillin-binding proteins 
PBS    Phosphate buffered saline 
PCR    Polymerase chain reaction 
PKG    Protein kinase G 
PMB    Para-methoxybenzyl  
RNA    Ribonucleic acid 
ROS    Reactive oxygen species 
SDS-PAGE   Sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
sGC    Soluble guanylyl cyclase 
SMCC    Succinimidyl-(N-maleimidomethyl) cyclohexane carboxylate 
SHV    Sulfhydryl variable type 1 
TAE    Tris-acetate-EDTA 
TB     Terrific broth 
TCEP    Tris(2-carboxyethyl) phosphine 
TEV    Tobacco etch virus 
TFA    Trifluoroacetic acid 
TLC    Thin layer chromatography 
U    Enzyme units 
UV    Ultraviolet 
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1.1 Discovery of nitric oxide 
 Nitric oxide (NO) was first discovered in 1772 by Joseph Priestly as an atmospheric 
pollutant and possible cause of acid rain.  In the 1980s, NO started to be investigated for 
medical applications and cell signalling. The Nobel Prize in Medicine or Physiology was 
awarded to Robert F. Furchgott, Ferid Murad and Louis J. Ignarro in 1998 for their discoveries 
related to “nitric oxide as a signalling molecule in the cardiovascular system”. In 1980, 
Furchgott was studying the effects of acetylcholine on vasodilation and noticed that blood 
vessels relaxed if endothelial cells were present. He proposed that a small factor produced by 
the endothelial cells relaxes the blood vessels and named it Endothelial Derived Relaxing 
Factor (EDRF).1 At around the same time, Murad was investigating the biological activities of 
nitroglycerin when he noted that it decomposes to NO and causes relaxation of smooth muscle.2 
Ignarro independently discovered that EDRF  was actually the gaseous molecule NO that 
causes vasodilation.3  These three discoveries motivated a great deal of research into the role 
of NO signalling in the cardiovascular system and led to several drugs for treating 
cardiovascular diseases, including glyceryl trinitrate for heart failure and molsidoamine to treat 
angina pectoris.4 
 
1.2 Physiological roles of nitric oxide  
 Nitric oxide is a colourless gas at room temperature and has a melting point of -163.6 oC 
and a boiling point of -151.8 oC.5  NO is a heteronuclear diatomic compound that exists as a 
free radical due to an unpaired electron.5 The gas is highly lipophilic and intrinsically reactive, 
with a half-life of only a few seconds in solution before it decomposes into oxygen and nitrogen 
gas. Nitric oxide readily diffuses through biological membranes without assistance from 
channels or receptors. It can be synthesised in the laboratory by reduction of nitric acid or 
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oxidation of ammonia. Relevant to this research project, NO is also a product of the 
spontaneous decomposition of diazeniumdiolates in aqueous physiological solutions.6-9 
 Nitric oxide acts as a potent signalling molecule involved in regulating the 
cardiovascular, nervous and immune systems.10 NO can also react with the thiol group of 
cysteine residues of some proteins; a non-enzymatic protein modification, that leads to S-
nitrosylation.11,12 NO is involved in maintaining physiological homeostasis, controlling aspects 
of vascular tone, neuronal communication, cell differentiation and apoptosis (Figure 1). 
 
 
Figure 1. Activities of NO in the cardiovascular, nervous and immune systems. 
 
1.3 Nitric oxide signalling 
 Endogenous NO is produced by nitric oxide synthases (NOS) from L-arginine via 
oxidation of the guanidine side chain.13 The oxidation process forms NO and L-citrulline via 
two successive mono-oxygenation reactions, with N-hydroxy L-arginine serving as an 
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intermediate.14 Three NOS isoforms are involved in regulating endogenous NO in the body: 
neuronal NOS (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS).15  nNOS and 
eNOS are constitutive NO generators, producing basal and short-lasting NO levels, whereas 
iNOS produces greater and longer-lasting NO concentrations. The resulting NO modulates 
many cell signalling pathways, such as the NO/sGC/cGMP,16 serine threonine protein kinase 
B(AKT),17 Ca2+/eNOS and nuclear factor kappa B(NF-κB)/iNOS.18 Constitutive NO is 
produced in the blood vessels by eNOS and is regulated by calcium and calmodulin levels. 
Changes in regulation can occur via phosphorylation, negative feedback and interactions with 
regulatory enzymes. In contrast, iNOS regulation occurs via inflammatory cytokines, oxidative 
stress and hypoxia.19 
The two pathways that regulate constitutive NOS both involve release of calcium from 
subsarcolemmal storage sites. The first pathway begins when shearing forces applied to the 
vascular endothelium by blood flow cause release of calcium and subsequent NOS activation.20 
The second involves stimulation of endothelial receptors by a variety of ligands, causing 
calcium release and NO production. Induction of iNOS occurs during inflammation and can 
cause NO levels to increase 1000-fold above constitutive levels.21 iNOS becomes active in 
several inflammatory states, including atherosclerosis, however, its role in cardiovascular 
inflammatory processes remains unclear.  NO produced constitutively and by iNOS in 
endothelial cells diffuses into adjacent smooth muscle, where it binds to its principal receptor 
soluble guanylate cyclase (sGC). NO binds to the β1 subunit of the α1β1 sGC heterodimer, 
activating the enzyme to convert GTP into cGMP (Figure 2).22 Another NO pathway converts 
the thiol group of protein cysteine residues to nitrosothiols, which serve as natural ligands for 
soluble guanylyl cyclase(sGC).23 Both pathways impact downstream signalling targets, such 





Figure 2. Sheer forces on endothelial cells cause an increase in intracellular Ca2+ release that 
activates NOS. NOS triggers the conversion of L-arg to L-cit and production of NO. The NO 
diffuses to and activates sGC, which converts GTP to cGMP. Ensuing PKG activation triggers 
a cascade that ultimately leads to vasodilation. 
  
1.4 Nitric oxide and cardiovascular disease 
 In the cardiovascular system, NO regulates vascular tone and myocardial contractility 
and acts to limit platelet aggregation.25,26 Vasodilation through the sGC–cGMP pathway is a 
prominent feature of NO signalling in the cardiovascular system. NO also affects circulating 
platelets and white blood cells and controls various cellular events, including platelet 
activation, mitochondrial function, ion transport, inflammation, angiogenesis and cell 
proliferation, all of which are important in cardiovascular homeostasis. NO regulates 
cardiovascular function through two distinct pathways: an indirect pathway that involves 
activation of sGC and downstream stimulation of PKG, and a direct pathway acting via 
S-nitrosylation of proteins.27 NO bioavailability is highly regulated by NOS and disruptions 
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can be caused by decreasing availability of L-arginine and NOS cofactors, increased levels of 
NO inhibitors or increased oxidative stress, causing NO degradation. Dysregulation of NO 
metabolism is a contributing factor in several vascular diseases, including atherosclerosis, 
hypertension and septic shock.28  
 
1.5 Current treatments using nitric oxide 
 There are three main ways to influence NO signalling in the body: (1) increase NO 
formation, (2) reduce NO breakdown and (3) directly stimulate NO downstream signalling 
targets.  Increased NO-mediated effects can be achieved by direct exposure to NO gas, use of 
inorganic nitrites, organic nitrates or other types of NO-donor compounds that spontaneously 
release NO in solution. 
 
 1.5.1 Inhaled NO  
 The use of inhaled NO was first proposed in 1991 as a method for achieving selective 
pulmonary vasodilation. Experiments were initially performed using animal (lamb) models of 
pulmonary hypertension and subsequently in humans.29 Selective pulmonary vasodilation is 
achievable partly because NO is scavenged by haemoglobin after diffusion into the blood. 
Inhaled NO reaching well-ventilated areas of the lungs improves ventilation–perfusion 
matching and increases blood oxygenation. Approximately 70% of inhaled NO is removed 
within 2 days of inhalation as nitrate in the urine.30  Inhaled NO is used today for the treatment 
of pulmonary hypertension in newborns, as well as in patients with congenital heart disease 
and after cardiac transplantation in adults.31,32 The gas can be delivered via a face mask, nasal 
cannula or endotracheal tube.33 
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 1.5.2 Inorganic nitrites 
 Nitrite has been known to cause vasodilation since Furchgott showed in 1953 that 
acidified sodium nitrite solutions are able to relax pre-constricted rabbit aortic strips.34  It is 
now known that nitrite contributes to the regulation of blood pressure and flow via its 
conversion to NO. Acidification of nitrite produces nitrous acid, which spontaneously 
decomposes to NO and other nitrogen oxides.35 The process is aided by iron or molybdenum 
metalloprotein oxidoreductases through electron transfer.36 There are at least three known 
sources of nitrite in mammals. Firstly, nitrite is an oxidation product of NOS-derived NO. 
Secondly, nitrite is present in some food products, including processed (cured) meats and green 
leafy vegetables.37 Thirdly, nitrite is generated by bacteria in the digestive system by nitrate 
reduction.38 Interestingly, NO generation from nitrite is known to be increased by vitamin C.39 
 
 1.5.3 Organic nitrates 
 Organic nitrates are nitric acid esters of mono- or polyhydric alcohols and represent the 
oldest clinically approved NO-based treatments.40 Nitrates essentially act as NO donor 
prodrugs and are commonly used to treat angina and coronary artery disease.  They exert their 
effects through enzyme bioactivation, producing NO that serves to relax vascular smooth 
muscle in both the arterial and venous circulation via the NO/sGC/cGMP pathway.  Organic 
nitrates can enter the circulation by absorption across mucous membranes, the gastrointestinal 
tract or the skin. Commonly used organic nitrates are nitroglycerin, isosorbide dinitrate, and 
isosorbide mononitrate. One of the issues with use of organic nitrates is the development of 
tolerance with prolonged therapy.41  Two hypothesis have been proposed for how tolerance 
develops: 1) superoxide anions produced during nitrate therapy cause inactivation of NO; 2) 




1.6 Clinically used NO donor drugs 
 Nitroglyercin (Figure 3) is a dense, colourless liquid that is typically produced by 
reacting glycerol with fuming nitric acid.  The compound was discovered in 1847 and was 
originally used as the active ingredient in gunpowder and explosives. For the last 130 years, 
nitroglycerin has been used medically as a potent vasodilator in patients with angina, 
hypertension and heart failure.41 Due to its half-life of 4 min in plasma and its biologically 
active metabolites half-life of 40 minutes,43 the drug can be delivered orally as a tablet, 
sublingually as a spray or transdermally as an ointment or patch. Release of NO from 
nitroglycerin is mediated by mitochondrial alcohol dehydrogenases. Although it contains three 
nitrate groups, nitroglycerin releases only one mole equivalent of NO from one of its terminal 
nitrates after bioactivation.44  
 Isosorbide dinitrate (Figure 3), first synthesised in 1939, is used as a vasodilator in the 
treatment of heart failure, oesophageal spasms and chest pain. It is usually taken orally, and its 
mechanism of action involves conversion to NO. Studies have shown that isosorbide dinitrate 
in combination with hydralazine is effective in treating African American patients with 
advanced heart failure.45-47 
 Sodium nitroprusside (Figure 3) is an arterial and venous vasodilator that has been used 
clinically for over 40 years. The compound acts as a prodrug, where it reacts with sulfhydryl 
groups to release nitric oxide, causing rapid vasodilation and acutely lowering blood pressure 
for up to 10 minutes. The drug is used in hypertensive crises, heart failure and  
paediatric/vascular/cardiac surgery.48 Experiments using frog hearts concluded that sodium 
nitroprusside activity can be enhanced by exposure to laser light.49,50  The metabolism of 






Figure 3. Structures of nitroglycerin (top left), isosorbide dinitrate (top right) and sodium 
nitroprusside (bottom). 
 
Another important NO-donor drug is molsidomine; a sydnonimine that has been used 
to treat angina pectoris for over 50 years. Molsidomine is a long-lasting, oral prodrug that 
releases the metabolite SIN-1 following reaction with liver esterases. SIN-1 then acts as a 
potent vasodilator through spontaneous release of NO (Scheme 1). The drug is also used to 




Scheme 1. Liver esterases promotes formation of NO from molsidomine via the intermediate 
SIN-1.  
 
1.7 Targeted delivery of NO 
 The clinical NO-donor drugs described above are non-selective agents that can affect 
all blood vessels exposed to the NO they produce. This can sometimes lead to a dangerous 
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lowering of blood pressure and potentially DNA damage.44 Accordingly, there has been 
significant research into the development of targeted therapies that can provide tissue-specific 
exposure to NO, with a focus in the areas of cancer therapy and inflammation. 
 
 1.7.1 Targeted NO therapy in cancer 
 The effects of NO on tumours is somewhat paradoxical. In some circumstances, high 
NO concentrations have been shown to be cytotoxic, while low concentrations have been 
shown in other studies to promote tumour growth.52 At low NO concentrations, NO promotes 
angiogenesis and anti-apoptotic effects. At high concentrations, NO can lead to cell-cycle arrest 
and apoptosis through DNA strand breaking, nitrosylation of enzyme cysteine residues and 
inhibition of mitochondrial activity.53 NO is known to react with superoxide to form 
peroxynitrite, which can react with tumour DNA leading to single strand breaks that trigger 
apoptosis.54  NO can also activate certain tumour-suppressing genes that reduce metastasis. At 
low concentrations, NO acts as a modulator of the tumour microenvironment, causing 
increased tumour size. At high concentrations, NO increases production of superoxide, 
hydrogen peroxide and peroxynitrite, which can damage ATP synthases in tumours leading to 
cell death. Peroxynitrite has been shown to nitrate tyrosine residues, generating 3-nitrotyrosines 
in proteins such as actin and superoxide dismutase. Nitrotyrosine is currently used as a 
biomarker for endogenous peroxynitrite activity.55 
In recent years there has been increasing interest in trying to incorporate NO into 
nanomaterials as a way of providing targeted NO therapy, where NO or NO-based prodrugs 
are locally released at tumour sites.56,57  Drug-loaded nanomaterials carry the advantages of 
being able to target tumours directly, resulting in reduced renal excretion, increased drug half-
life and generating high local drug concentrations at the tumour site. In one example, S-
nitrosoglutathione was loaded into calcium carbonate-mineralised nanoparticles, which allow 
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the NO donor to achieve much longer blood circulation times and provide a more sustained 
NO release, compared to direct administration of NO donors.56 The acid environment of 
endosomes in cancer cells serves to activate S-nitrosoglutathione and generate high 
concentrations of NO at the tumour site. The NO can diffuse to the surrounding blood vessels 
where it promotes vasodilation, providing better access for the nanoparticles and anti-cancer 
drug to the tumour leading to apoptosis (Figure 4).58  
 
Figure 4. Nanoparticles loaded with S-nitrosoglutathione and an anticancer drug enter the 
tumour from the blood stream. The acid environment of the tumour acts to stimulate release of 
NO, which diffuses out of the tumour and causes localised vasodilation. This enables greater 




A selection of hybrid drugs that contain NO have been developed for targeted 
vasodilation, such as COX-inhibitor-NO59 and statin-inhibitor-NO.44 The purpose of these 
hybrid drugs is to maintain the potency of the native drug action and achieve the right 
concentration of NO at the site of action. The materials containing NO prodrugs are designed 
to enhance endothelial cell growth, decrease smooth muscle cell proliferation and cellular 
adhesion. NBS-1120 is a NO/H2S releasing hybrid that inhibits proliferation by affecting the 




 1.7.2 Targeted NO therapy in cardiovascular disease 
 In section 1.6, clinically used NO-donor drugs were described that provide indirect NO 
treatment of cardiovascular diseases. In the last decade, new targeted NO therapies have been 
designed as more direct treatments.  Nicorandil is a dual-acting nicotinamide nitrate ester that 
acts as a NO donor and targets ATP-sensitive potassium channels and is used to treat angina. 
The appended nitrate ester moiety acts as a source of NO that stimulates soluble guanylyl 
cyclase activity. The compound also acts as an ATP-sensitive potassium channel opener 
causing surrounding veins and coronary arteries to dilate. Nicorandil has been shown to provide 
cardioprotective properties for up to 1.6 years by improving fibrinolysis and reducing the risk 
of thrombus formation.61 
 
 
Figure 5. Structure of nicorandil, a dual-action NO donor drug used to treat angina. 
 
1.8 Diazeniumdiolates (NONOates): a versatile class of NO donors 
 The first diazeniumdiolate (NONOate) NO donor compound was synthesised in 1960 
as an adduct formed in the reaction between diethylamine and NO gas under pressure.62 
Diazeniumdiolates consist of a diolate group [N(O-) N=O] bound to an amine. Potential 
medical applications were discovered in the 1990s when it was found that the 
diazeniumdiolates spontaneously decompose in aqueous solution at physiological pH and 
temperature to generate up to 2 mole equivalents of NO (Scheme 2).63 Keefer and co-workers 
have described a range of diazeniumdiolates with half-lives varying from seconds to hours,6-
9,64 whose rates of NO release follow first-order kinetics. The released NO can influence a 
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range of biological effects, including vasodilation, inhibition of platelet aggregation and blood 
coagulation. Diethylamino diazeniumdiolate (DEA-NONOate) was shown to prevent and 
reverse vasospasm in a primate model of subarachnoid haemorrhage without affecting systemic 
blood pressure.65 A clinical focus for NONOates has been in the prevention of thrombosis and 
neointimal formation following vascular injury. A recent study described a 'bump and hole' 
strategy for delivering targeted NO using an enzyme-triggered prodrug; galactosidase-








 Recently, a metal NONOate Ni(SalPipNONO) was shown to have potential antitumor 
activity. When Ni(SalPipNONO) enters tumour cells, the NO released causes a burst of 
intracellular reactive oxygen species (ROS), leading to apoptosis and arrested migration.  More 
than 90% of cells were killed by Ni(SalPipNONO) compared to untreated controls and reduced 
blood vessel development was also observed.67 
JS-K is a targeted NONOate carrying an O-arylated diazeniumdiolate. JS-K contains 
the 2,4-dinitrophenyl group, which is cleaved off in the presence of glutathione (GSH) in a 
reaction catalysed by glutathione-S-transferase (GST). GST is overexpressed in tumour cells; 
thus JS-K is designed to be selectively activated in tumours. Release of 2 moles of NO causes 






Scheme 3.  Reaction of JS-K with GSH in tumour cells to release 2 moles of NO.68 
 
1.9 β-lactamases   
 β-lactamases are enzymes that catalyse the irreversible inactivation of β-lactam 
antibiotics by hydrolytic opening of the azetidin-2-one (β-lactam) ring. Antibiotics containing 
a β-lactam ring (such as cephalosporins, see 1.10) interfere with the biosynthesis of 
peptidoglycan in bacterial cells by binding and acylating the active site serine nucleophiles of 
penicillin-binding proteins (PBPs), thus preventing cell wall cross-linking.69 The weakened 
bacterial cells lyse due to an inability to counter intracellular osmotic pressure. Bacteria have 
evolved the ability to destroy these antibiotics through the production of β-lactamases, which 
inactivate the antibiotics (through β-lactam hydrolysis) before they can react with PBPs.70 
 β-lactamases employ a simple mechanism whereby nucleophilic addition at the 
carbonyl carbon of the β-lactam ring occurs through reaction with an active-site serine in the 
β-lactamase, leading to cleavage of the β-lactam C-N bond.71 The serine is subsequently 
deacylated via water-mediated hydrolysis to reactivate the β-lactamase for further reaction with 
another β-lactam molecule (Scheme 4).72  
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Scheme 4. Mechanism for β-lactam ring opening by active-site serine nucleophiles in β-
lactamases. 
 
 β-lactamases are divided into four classes (A, B, C, D) based on their amino acid 
sequences. β-lactamases can be divided mechanistically into the serine enzymes and zinc 
enzymes.73 Serine β-lactamase contain a serine residue in the active site and form an acyl-
enzyme intermediate during catalysis. Zinc β-lactamases form a non-covalent bond with the β-
lactam through interactions between the carbonyl group and a zinc metal ion. Serine β-
lactamases are sub-divided into three classes; A, C and D, while zinc β-lactamase are all from 
class B.74 
 
1.10 Cephalosporins  
 Cephalosporins are an important class of clinically useful antibiotics that contain a β-
lactam fused to a dihydrothiazine ring. Cephalosporins exert antibacterial activity by binding 
to bacterial penicillin-binding proteins (PBPs).75 Cephalosporins undergo β-lactam ring-
opening when they acylate transpeptidases and a cis-conformation at the C6 and C7 positions 
in the β-lactam ring is required for activity. 
 Cephalosporins are classified into five generations based on their era of development 
and their ability to treat Gram-positive and Gram-negative infections. The older, first 
generation cephalosporins are typically more effective against Gram-positive bacteria, while 
later generation compounds are active against Gram-negatives. First generation 
cephalosporins, such as cephalexin and cephalothin (Figure 6), are used to treat Gram-positive 
cocci.76 They can be used orally to treat tissue infections, have a half-life of more than 1 hour 
and are typically administered every 6-8 hours. Many bacteria have developed β-lactamase-
mediated resistance to cephalosporins, making early generation cephalosporin treatments less 
16 
 
effective these days. Side-chain modification of cephalosporins can alter antimicrobial activity 
and resistance to β-lactamases, as was done to create the later generation compounds.77  
  
 
Figure 6.  Structures of two first-generation cephalosporins. 
  
 Cephalosporins can be used as prodrug scaffolds, where effector drugs are attached at 
the C3'-position. When the cephalosporin is hydrolysed by PBPs, β-lactamases or other 
nucleophiles, the cephalosporin undergoes β-lactam ring opening, causing the effector drug 
attached at the C3′-position to be released via a conjugate elimination reaction.  
 
1.11 Cephalosporin-3′-diazeniumdiolate NO donor prodrugs 
Cephalosporin-based NO-donor prodrugs have been a major research area in the Kelso 
Research Group at The University of Wollongong for the past decade. The group has created 
prodrugs that release a diazeniumdiolate NO-donor from cephalosporins upon reaction with β-
lactamases. These cephalosporin-3′-diazeniumdiolates (C3Ds) are being explored as a new way 
of treating chronic infections due to the ability of NO to trigger dispersion of bacterial 
biofilms.78,79 The diazeniumdiolate NO-donor moiety is covalently attached to the 
cephalosporin 3′-position via its terminal oxygen, creating a chemically stable prodrug. The 
diazeniumdiolate is released from the prodrug after cleavage of the O-C bond, which occurs 
via rapid conjugation elimination following β-lactam hydrolysis (Scheme 5). The 
diazeniumdiolate then spontaneously fragments to produce 2 moles of NO and the constituent 
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secondary amine (e.g. pyrrolidine in PYRRO-NO). Some diazeniumdiolates have a very short 




Scheme 5. Mechanism of β-lactamase-triggered NO release from cephalosporin-3′-
diazeniumdiolate NO donor prodrug PYRRO-C3D.78 
 
1.12 Antibody dependent enzyme prodrug therapy (ADEPT)  
 Antibody-directed enzyme–prodrug therapy is a drug targeting approach where an 
enzyme is targeted to a tissue in the body by conjugation to a tissue-specific antibody. Once 
localised at the tissue, the enzyme serves to site-selectively activate a prodrug.1 The ADEPT 
concept was first hinted at in 1906 by Paul Ehrlich when he proposed the ‘magic bullet’ theory 
of targeting therapeutic agents to specific tissues to increase their potency and selective activity 
and to reduce toxicity.  ADEPT wasn’t really considered further until Bagshawe demonstrated 
the concept in the late 1980s.81-83 Here, Bagshawe conjugated bacterial carboxypeptidase G2 
(CPG2), an enzyme that catalyses the conversion of folates to pteroates and L-glutamate, to a 
F(ab')2 antibody fragment of a monoclonal antibody that had been raised to human chorionic 
gonadotrophin. The antibody portion served to target the conjugate to colon and rectal tumours 
when injected into mice. After the antibody CPG2 conjugate had localised at the tumour site 
and excess conjugate was cleared from the blood, para-N-bis(2-chloroethyl) amino 
benzoylglutamic acid (a nitrogen mustard cytotoxin prodrug) was introduced, which was 
cleaved to the active mustard cytotoxin by the CPG2 localised at the tumour via the antibody.  
A few years later, Bagshawe and Senter independently reported ADEPT strategies using 
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alkaline phosphatase conjugated to two tumour-targeting monoclonal antibodies, L6 and 1F5. 
The conjugates were able to dephosphorylate the prodrugs mitomycin phosphate and etoposide 
phosphate, respectively, into the active cytotoxins mitomycin and etoposide. The prodrugs 
were shown to be less toxic to cells than the parent cytotoxins and stronger antitumor responses 
were seen with the conjugates.84 
ADEPT techniques have explored conjugates of monoclonal antibodies with a wide 
range of modalities, ranging from enzymes, drugs and radionuclides to genetically engineered 
fusion proteins. All ADEPT techniques are designed to produce higher concentrations of active 
drug at the target site than other tissues in the body in order to lower exposure of non-target 
tissues to the drug.85  When ADEPT is used in cancer, selectivity for the tumour is achieved by 
the antibody binding to an antigen that is uniquely expressed on the surface of the tumour 
cells.86 The approach carries several advantages in cancer treatment, including : 1) a bystander 
effect, where an active small molecule drug diffuses throughout the tumour, thereby killing 
surrounding tumour cells that may not express the tumour antigen87 2) an amplification step, 
where one enzyme molecule locally converts many prodrug molecules into their active form 
and 3) systemic toxicity is reduced because the active drug is generated selectively at the 
tumour site.85 The main disadvantage of ADEPT is that antibody-enzyme conjugates can be 
immunogenic. Other challenges for ADEPT include drug resistance, toxicity from the immune 
system and antigen downregulation.88 
An example of ADEPT using a cephalothin-primaquine prodrug with an antibody-β-
lactamase conjugate is provided in Figure 7.89 The first step in this approach involves injecting 
a monoclonal antibody-β-lactamase conjugate with high affinity for a targeted antigen into the 
host. One administered, the cephalothin-primaquine prodrug is converted to the active drug 







Figure 7. Example of ADEPT using a cephalothin-primaquine prodrug with an antibody-β-
lactamase conjugate.89 
 
 ADEPT efforts have focussed on achieving greater tissue selectivity through 
modification of the monoclonal antibody (or fragments) to increase binding to the target of 
interest. Antibodies ‘humanized’ by replacing the murine regions with complementarity 
determining regions from human antibodies have also been investigated,90 along with 
antibodies simplified into single chains, F(ab')2 fragments or variable region fragments (Fv).
91    
 Recently, ADEPT conjugates have been produced where enzymes are fused to a single-
chain antibody (scFv).92,93 This type of fusion protein has the same selectivity as the whole 
monoclonal antibody but slows circulatory clearance and minimises immunogenicity. 
Recombinant fusion proteins can be reproducibly expressed in useful quantities and can be 
tailored to control pharmacokinetics and overcome other hurdles, such as tumour distribution.94 
A novel glyceridase with epitopes removed to bypass the immune system recently opened up 
new possibilities for ADEPT.95 In one study, a conjugate was made by fusing a single chain 
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fragment from a second-generation murine antibody to a β-lactamase, where the enzyme acts 
as a reporter for gene expression.96.  
 
1.13 Long term goals  
 Our long-term goal is to create an antibody-enzyme conjugate for use in ADEPT that 
provides targeted delivery of vasodilating NO for the emergency treatment of acute-atheroma-
induced coronary artery occlusions that cause heart attacks. We propose that a single chain 
antibody fragment that targets atherosclerotic plaques (designed by Karlheinz Peter)97-101 could 
be conjugated to a β-lactamase. Upon binding of the conjugate to a coronary artery-occluding 
plaque, the β-lactamase portion could serve to activate a co-administered C3D, causing locally 
raised NO concentrations around the plaque site. This concentrated burst of NO could produce 
a powerful vasodilation event around the plaque, potentially restoring blood flow through the 
blocked artery and providing temporary relief from myocardial hypoxia. If used as an 
emergency intervention during an atheroma-induced heart attack, the approach could keep 
patients alive long enough to undergo emergency surgery to physically resolve the blockage 





Figure 8. ADEPT strategy for emergency intervention during of heart attacks caused by 
atheroma-induced coronary artery occlusion. An atheroma-targeting scFv-β-lactamase 
conjugate and is used with a C3D to target vasodilating NO to occluded sites. 
 
1.14 Thesis Aims  
 
 Since the discovery of NO as a potent vasodilator, many clinically useful drugs have 
been developed, including nitroglycerin and sodium nitroprusside, to treat cardiovascular 
diseases. There is, however, an unmet need for targeted NO technologies that can selectively 
release NO at specific tissue locations. ADEPT is a technology that could enable such targeted 
delivery. In this project, a new ADEPT strategy was explored that uses a C3D NO-donor with 
a β-lactamase conjugated to an antibody. The specific aims of this project were to: 1) design, 
clone and express useable quantities of a suitable β-lactamase, 2) conjugate the β-lactamase to 
a model  Fab'-528 antibody fragment, 3) synthesise and purify a cephalosporin-3′-
diazeniumdiolate (DEA-C3D) and 4) demonstrate NO release from DEA-C3D in the presence 
of the Fab'-528-β-lactamase conjugate.  The overarching goal was to show for the first time 
that a β-lactamase enzyme conjugated to a (model) antibody fragment can trigger NO release 
from a C3D. This preliminary proof-of-concept study, if successful, would motivate 
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downstream translational ADEPT studies aimed at producing a clinical intervention for 




















Chapter 2: Cloning, expression and 






 As described in section 1.9, there are several classes of β-lactamase that catalyse the 
ring opening of β-lactam antibiotics, including cephalosporins. TEM-1 β-lactamase was 
selected for use in this study due to its high expression levels and cephalosporinase activity, 
being a class A enzyme. A soluble, highly purified, functionally active and stable recombinant 
TEM-1 β-lactamase was required for the protein bioconjugation and NO release studies. For 
this work, electrocompetent bacterial cells, E. coli, were used for gene cloning and protein 
expression. E. coli cells were chosen due to their well-established culturing methods, simple 
nutrient requirement, easy of scalability and affordability. A flowchart depicting the cloning, 
expression and purification of a recombinant TEM-1 β-lactamase is provided in Figure 9.   
 
 
Figure 9. Flowchart showing the steps of transformation, expression and purification used to 





2.2 Gene and Vector design 
 I acknowledge Stewart Nuttall (CSIRO) for design of the vectors used for TEM-1 β-
lactamase production. A suitable β-lactamase gene for cloning was obtained from published 
research that used this gene to express TEM-1 β-lactamase protein that was then used for X-
ray crystallographic studies, an X-ray crystal structure was reported.102,103 Protein sequences 
were searched via the protein database and Uniprot. TEM-1 β-lactamase with a 100% 
confirmed primary sequencing was reported by Adachi.104 The protein was modified to replace 
the N-terminal NusA solubility tag with an N-terminal hexa-histidine (Hisx6) tag followed by 
a Tobacco Etch Virus (TEV) protease cleavage site upstream of the main gene. The signal 
peptide, identified as amino acids 1-23 in the β-lactamase sequence, was removed to allow the 
enzyme to be expressed intracellularly and preventing the β-lactamase from exiting the cell. 
As the β-lactamase is produced intercellularly, the project can be safely conducted in-house.  
The wild-type TEM-1 β-lactamase vector was chemically synthesised by GenScript and 









 The construct contained the N-terminal Hisx6-tag (red) to facilitate purification of the 
recombinant protein using immobilised metal affinity chromatography (IMAC). The TEV 
protease cleavage site (blue) allowed for removal of the Hisx6-tag from the purified protein by 
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the highly specific Tobacco Etch Virus (TEV) cysteine protease. The construct also contained 
a BamH1 restriction enzyme site (purple) before the main protein sequence (green) and ended 
with a Nhe1 restriction enzyme site (orange) followed by stop codons. Theoretical data for the 
TEM-1 β-lactamase are displayed in Table 1 (Note: prior to TEV cleavage). A start codon (M) 
was also included before the His tag, along with a few amino acids between the His tag and 
TEV cleavage site to allow the Hisx6-tag to protrude from the main protein structure and bind 
to nickel during IMAC purification. Three TEM-1 β-lactamase constructs were originally 
considered for use in the study (Figure 10).   
 
 
Figure 10. Constructs 1, 2 and 3 proposed by Stewart Nuttall (CSIRO) for cloning and 
expression of a recombinant TEM-1 β-lactamase. Theoretical data (i.e. molecular weight, pI, 
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number of cysteines and extinction coefficients) for the proteins coded by the constructs are 
provided in Table 1. 
 












No. of amino acids 290 385 385 
Molecular weight 31876.11 42721.38 42675.29 
pI 5.73 5.50 5.50 
No. of cysteines 2 (bonded) 2 (bonded) 1 (free) 2 (bonded) 
Extinction 
coefficient 
29575 30940 31065 
Stability index 39.86 (stable) 43.57 (unstable) 44.21 (unstable) 
 
 The modified pET43.1a vector was kindly provided by CSIRO. This vector is similar 
to the pET 43.1 a+ created by Novagen (Appendix 1), except GGGG and GGCG tags were 
added to the N-terminus just before the main protein sequence. The vector also contains a 
SUMO gene between the TEV gene and the GGGG or GGCG tags to aid protein solubility. 
The vector contains the origin of replication (F1), a lac promotor site that is induced using 
IPTG and an ampicillin resistance gene, which allows the vector to express in E. coli. The 
pET43.1a vector is a simple way to create the three proposed constructs of TEM-1 β-lactamase. 
Construct 1 was designed as a β-lactamase control. Construct 2 was designed to allow 
intermolecular disulfide bonding through the thiol group of the cysteines in β-lactamase with 
another protein containing a free thiol group. Construct 3 was designed to enable Sortase-
mediated bioconjugation (5.2.1.2). Different selection markers were considered, such as 
ampicillin, capreomycin and kanamycin, however, ampicillin was ultimately chosen as the 
selective marker as unpublished studies from CSIRO shows that ampicillin provides the highest 




2.3 Digestion of recombinant TEM-1 β-lactamase insert and vector 
 I acknowledge Regina Surjadi for assistance in digesting the TEM-1 β-lactamase insert 
and vector and Luisa Pontes-Braz and Anna Raicevic for help in troubleshooting. Recombinant 
TEM-1 β-lactamase was expressed through a cloning cell line created by digesting the gene 
from the cloning vector provided by Genscript. The cloning vector containing the TEM-1 β-
lactamase insert was mixed with restriction enzymes, BamH1 and Nde1 to excise the vector at 
the restriction enzyme sites (2.2). The BamH1 and Nde1 restriction enzymes were used at 20 
U/µL. The optimal concentrations of restriction enzymes were 10 units of enzyme per µg DNA 
for a 1-hour digest.  For a vector concentration of 160 ng/µL, 10 U of both restriction enzymes 
were used for 1.5 hours to ensure that the insert was cleanly cut from the vector. The digestion 
was performed at 37 oC as this is the best temperature for restriction enzyme activity. The 
digested mixture was loaded onto a standard 1% agarose DNA gel with 1:10,000 SYBR safe 
dye. SYBR safe dye binds to DNA like ethidium bromide but is less toxic. A DNA ladder was 
loaded into another lane (100 bps to 1517 bps). For complete digestion, the insert band was 
expected at 870 bps. The DNA gel was run at 110 V for 30 minutes and imaged at 500 to 600 
nm (Figure 11). This TEM-1 β-lactamase  insert was recovered from the DNA gel and used for 
ligation. Similarly, the modified pET43.1a vectors containing the GGCG and GGGG tags 
(constructs 2 and 3, respectively) were digested and the open vectors recovered using the same 
procedure and conditions as construct 1. The insert from the pET43.1a vectors were not 




















Figure 11. DNA agarose gel showing the digestion of the TEM-1 β-lactamase cloning vector 
using BamH1 and Nde1. Lane 1 shows the DNA ladder with a bps marker ladder on the side. 
Lane 2 is the digested sample showing a clean insert band with the expected size (~870 bps). 
 
2.4 Agarose gel electrophoresis and DNA fragment purification 
 I acknowledge Regina Surjadi for assistance in the DNA fragment purification of the 
TEM-1 β-lactamase vector. Agarose gel electrophoresis is the preferred method for 
determining the size of DNA and for extracting DNA fragments. DNA fragment samples and 
PCR mixtures were mixed with 4x DNA loading dye and loaded in separate wells on an agarose 
gel. All experiments were performed in 1x TAE buffer with a GeneRuler 1kB Plus DNA ladder 
included and were run at 150 V for 40 minutes. The gels were visualised using an Odyssey Fc 
imaging system, LI-COR, at 600 nm. Positive clones were identified as higher running bands 
on the gel than the parental clones (negative controls). Sizes of the plasmids were confirmed 
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by comparison to the DNA ladder. DNA fragments were excised under a UV lamp using a gel 
knife to isolate individual bands. The DNA fragment was purified using NucleoSpin Gel and 
PCR Clean-Up according to the manufacturer's instructions. The kit contains a high-salt buffer 
that dissolves the gel containing the DNA. The DNA is then bound to the silica column and 
ethanol solution is used to wash away any impurities. The pure DNA is then eluted under low 
ionic strength conditions with slightly alkaline buffer (5 mM Tris/HCl, pH 8.5). 
  
2.5 Quantification of DNA insert and vector 
 DNA insert and vector concentrations can be quantified using the Nanodrop 2000 
spectrometer (Thermo Fisher). DNA concentrations are calculated from the absorbance at 260 
nm using the Beer-Lambert Law, (A= εcl) and DNA purity is determined by the absorbance 
ratio at 280 nm and 260 nm. The size of the DNA is determined by the position where the DNA 
stops migrating in an agarose gel and comparison to DNA molecular weight (MW) markers. 
As DNA has a negatively charged phosphate backbone and moves towards the anode, smaller 
DNA strands move faster through the gel and larger DNA fragments run more slowly. A DNA 
MW ladder run in a separate lane is used to determine the size of each DNA band. High quality 
DNA should have a ratio between 1.8-2.0 for the 280 nm/260 nm ratio which inform the correct 
AT to CG base pairs. A sample of 1-2 µL was loaded onto the Nanodrop to measure the DNA 
concentration. TEM-1 β-lactamase insert, and open vector concentration are displayed in Table 
2.  
   
Table 2. Concentration of TEM-1 β-lactamase inserts and open vectors obtained using the 
Nanodrop. 














2.6 Cloning recombinant TEM-1 β-lactamase  
 I acknowledge Regina Surjadi for assistance in cloning the TEM-1 β-lactamase. The 
purified insert DNA and open vector DNA could be ligated together due to their compatible 
sticky ends since the same restriction enzymes were used for digestion. The TEM-1 β-
lactamase insert was used to ligate to both opening vectors. A T4 DNA ligase is used to join 
the phosphate backbones when the complementary bases are aligned. Molar ratios of 1:1, 3:1 
and 5:1 of insert: vector were examined but only the 5:1 ratio gave successful ligation, as 
determined by DNA electrophoresis gel (see 2.4). The enzyme activity of T4 ligase used in all 
trials was 10 kU.  
 Transformation is the process wherein a newly designed vector is introduced into host 
bacterial cells in order to express the recombinant protein of interest. Construct 1, 2 and 3 
plasmids were transformed into DH5-α E. coli cells. The competent DH5-α cells have a porous 
membrane when heat-shocked, which allows the supercoiled plasmids to enter the cells with 
high transformation efficiency. A standard heat shock method was applied that involved 
placing the cells on ice for 10 minutes, applying a heat shock at 42 oC for 45 seconds and 
returning to the ice for another 2 minutes. The transformed cells were supplemented with 
nutrient rich 2x YT with ampicillin. The cells were streaked onto YT-Amp agar plates with the 
ampicillin selective marker to develop single colonies overnight. The plates were incubated 
upside down in the 37 oC incubator to prevent condensation of water and contamination. The 
doubling time for E. coli is 20 minutes and a visible colony can develop on the agar plates 
within 16 hours. A negative control plate was also incubated using undigested pET 43.1 a. 
Colonies were formed as spherical white nodules on the agar plates and random colonies were 




2.7 Colony screening for positive TEM-1 β-lactamase clones 
 I acknowledge Regina Surjadi for assistance in colony screening for the TEM-1 β-
lactamase vector. Potential positive clones were identified through colony PCR on the 
transformants. Random colonies from each transformation plate, along with the control plates, 
were selected from 2.5 and screened for positive TEM-1 β-lactamase clones. A Master Mix 
was created containing 5 µL of 2xGoTaq® Green (GTG), 0.5 µL of T7 Forward primers (10 
µM), 0.5 µL of Coli Down , a reverse primer, (10 µM) and 4 µL of distilled water for each 
colony to undergo PCR. The reverse primer binds to the stop codon of the β-lactamase gene 
and read the codon backwards for PCR. Each colony was dipped into separate 10 µL aliquots 
of the Master Mix in PCR tubes and placed into the PCR machine. Annealing temperatures for 
the PCR reactions were obtained using an online calculator that estimates the melting 
temperature based on the percentage of cytosine and guanine bases in the primers. Each colony 
in the reaction mixture was amplified using 25 cycles using the conditions outlined in Table 3. 
Table 3. PCR parameters for gene amplification. 
Step Temperature 
(oC) 
Time per sample 
(sec) 
Number of Cycles 
Initial 
denaturation 
94 30 1 
Denaturation 94 30  
25 Annealing 55 30 
Extension 72 90 
Final Extension 72 240 1 
 
 Colonies were streaked onto YT-Amp agar patch plates and incubated at 37 oC 
overnight. The reaction mixtures were analysed on a 1% (w/v) agarose gel with 1:10,000 SYBR 
Safe dye made up in Tris-acetate-EDTA (TAE) buffer to determine the positive clones. A 
bacterial colony with positive transformation was streak purified and stored long-term in LB 




2.8 DNA Sequencing  
 I acknowledge Regina Surjadi for assistance in DNA sequencing. DNA sequencing was 
used to confirm whether the entire sequence had inserted correctly into the expressing vector. 
Samples of the positive clone identified from the agarose gels in 2.7 were grown up in sterile 
YT-Amp media overnight at 37 oC from the overnight patch plate.  The DNA was then 
extracted by centrifugation at 4,000 rpm for 10 min at 4 oC and a Miniprep was performed on 
the pellet.  Polymerase Chain Reaction (PCR) (Perkin Elmer GeneAmp 9600 PCR System 
Thermal Cycler) was performed on the purified DNA to amplify the DNA concentration. 
Purified DNA of positive clones was sent to Micromon (Monash University, Victoria, 
Australia) for Sanger DNA sequencing. The DNA sequencing was performed using the T4 
reverse primer as the β-lactamase was at the downstream end of the plasmid. 10 µL samples of 
DNA were sent fresh from the Miniprep extraction as the DNA degrades over time.  The rest 
of the samples were stored in the -20 oC freezer until completion of the sequencing. DNA 
sequencing chromatograms analysed using Chromas. Chromas provided three different 
sequences, one for each reading frame. The correct reading frame was aligned to the theoretical 
DNA sequence using BLAST. DNA that aligned correctly indicated that the corresponding cell 
colony had transformed successfully and could be used for protein expression. DNA 
sequencing results for the β-lactamase constructs 1-3 are provided in Appendix 2. 
 
2.9 Analytical protein expression studies 
I acknowledge Regina Surjadi for assistance in small-scale analytical protein 
expression. A small-scale analytical protein expression with the positive clones was performed 
to determine whether the three β-lactamase constructs express the correct, enzymatically active 
protein. The DNA plasmids confirmed by Sanger sequencing from 2.8 were transformed into 
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E. coli BL21-DE3 cells using the heat-shock method and incubated on YT-Amp plates 
overnight at 37 oC. One overnight colony from each construct was selected and grown in fresh 
5 mL of 2 x YT media at 37 oC until an OD of 0.8 was reached before the sample was induced 
with 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). The overnight colony plates were 
sealed and kept in the refrigerator for further expression experiments. IPTG causes 
overexpression of the β-lactamase construct at 16 oC overnight and allows correct folding of 
the enzyme. Cells were centrifuged and the pellets lysed with Bugbuster to extract the 
overexpressed β-lactamase protein. The lysate was centrifuged briefly and the supernatant 
containing the β-lactamase protein was extracted. Sodium dodecyl sulfate (SDS)-gel and 
Western blot analyses were performed to determine whether the expressed enzyme had the 
correct sizes. The SDS gel and Western blot showing the expression of the three β-lactamase 
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Figure 12. (A) SDS gel and (B) Western blot of the analytical expression of the three constructs 
respectively. Samples were loaded in duplicate. NuPAGE 4-12% precast gel was used. Lane 1 
= SeeBlue 2 Ladder. Lane 2 and 3 = duplicate samples of the expressed His-TEV-β-lactamase 
construct. Lane 4 and 5 = His-TEV-SUMO-GGGG- β-lactamase construct. Lane 6 and 7 = His-
TEV-SUMO- GGCG- β-lactamase construct. 
 
 SDS gel and Western blot were performed on the crude lysates from the E. coli cells. 
In lanes 2 and 3 in the SDS gel, a dark band above the 28-kDa marker corresponded to the His-
TEV-β-lactamase. The corresponding lanes in the anti-His tag Western blot showed the same 
size band, confirming that the His-TEV-β-lactamase construct was expressing well. A band 
below the 49 kDa marker in lanes 2 and 3 in both the SDS gel and Western blot suggested that 
the sample may contain endogenous proteins with a high number of histidine residues or that 
the expressed β-lactamase is aggregating to some extent. Lanes 4 and 5 showed a major band 
just below the 49 kDa marker, which corresponded to the His-TEV-SUMO-GGGG-β-
lactamase (construct 3). Similarly, lanes 6 and 7 showed the same band as in lane 4, consistent 
with the very small difference in the constructs 2 and 3 (i.e. substitution of one glycine residue 
to a cysteine residue). However, the two constructs also showed a band around 98 kDa in both 
  1    2    3    4     5    6     7 
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the SDS gel and Western blot, suggesting that the proteins were forming dimers. This was more 
prominent in lanes 6 and 7, which may indicate that the newly introduced cysteine residue was 
forming an intermolecular disulfide bond. It is possible that a small amount of protein leaked 
from the adjacent well and that the band at 49 kDa is not aggregation.  We suspect that 
increasing the size of the protein by adding the SUMO gene may have contributed to increased 
dimerisation. Due to this dimerization issue, only the His-TEV-β-lactamase construct 1 was 
advanced to large-scale protein expression and bioconjugation studies. 
 
2.10 SDS-Page Gels and Western Blotting 
 I acknowledge Dr. Bill McKinstry for his expert tips on SDS-PAGE gels and Western 
blots. SDS-gel and Western blot analysis was used to detect whether the BL21 DE3 cells were 
expressing the correct TEM-1 β-lactamase. SDS denatures proteins and coats them with a 
negative charge, allowing migration through gels based on molecular size when a voltage is 
applied. The size of the protein determines how fast and how far down the gel the protein 
migrates, with smaller proteins moving further than larger proteins. All SDS-gels and Western 
blots were performed using commercially available NuPAGE 6-12% Bis-Tris gels. A 
commercial standard See Plus 2 MW marker ladder was added to the first lane of each gel. 
This ladder contains a mixture of proteins of defined molecular weights and was used to 
estimate the sizes of proteins, including the expressed TEM-1 β-lactamase. Coomassie stain 
was used to visualise the proteins on the SDS gel. Washing with 10 % ethanol/7.5 % glacial 
acetic acid (v/v) to remove excess stain allowed clear visualisation of the protein bands and 
ladder.  
 Western blot was performed to confirm the protein of interest within the gel using a 
specific antigen conjugated to a reporter enzyme. Chemilluminescent Western blot was used 
to detect the TEM-1 β-lactamase as it is a sensitive assay. The SDS gel was transferred to a 
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nitrocellulose membrane using a Western blot transfer tank running at 25 V for 90 minutes. 
The nitrocellulose membrane was blocked with milk powder solution as a cheap, arbitrary 
protein source. Detection used a, anti-His- horseradish peroxidase (HRP) antibody conjugate 
that recognises and binds to poly-histidine epitopes (Hisx6 and Hisx10). The only protein on 
the membrane with a poly-His tag and expected to be bound by the antibody is the TEM-1 β-
lactamase. HRP chemiluminescence substrate (Super-signal West Pico PLUS) was then added 
to the membrane. The chemiluminescence substrate contains luminol, which is the limiting 
substrate for HRP and produces a light-emitting product. The membrane was imaged 
immediately at 425 nm. The band that lit up from the imaging system corresponded to the 
TEM-1 β-lactamase. The purity of the sample was determined by comparing the Western blot 
and the Coomassie blue-stained SDS gels. 
 
2.11 Large scale TEM-1 β-lactamase expression 
 I acknowledge Dr. Bill McKinstry for assistance in the large scale β-lactamase 
expression. The SDS-gel of the small-scale expression of the three constructs (section 2.9) 
showed that only the wild type His-TEV-β-lactamase had one major protein band, compared 
to the other constructs.  Therefore, only the His-TEV-β-lactamase (hereafter referred to as 
TEM-1 β-lactamase) was carried forward to large scale expression and purification.  The YT-
Amp colony plate of TEM-1 β-lactamase used for the small-scale expression was thawed and 
another colony picked and incubated with 12.5 mL of 2x YT-Amp medium overnight at 37 oC. 
The overnight culture was used to inoculate one litre of TB media containing 10% potassium 
chloride salt. The potassium phosphate was included in the media to act as a buffer to delay 
alkalization and entry of cells into the death phase.105 E. coli cells were incubated in TB as it 
contains glycerol as a carbon source, releasing acid when metabolised and delaying 
alkalization. The OD for the TB starting culture was 0.1, corresponding to the bacteria’s growth 
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phase. The one litre culture was split into two 500 mL Turnair flasks and shaken in the 
incubator at 180 rpm at 37 oC to allow better aeration. Shaking and aeration are required to 
prevent the cells from settling to the bottom of the flask, which can increase cell death due to 
nutrient shortage and low oxygen.  The cultures were grown to OD 0.7-0.8 was achieved, where 
the bacteria are in mid-logarithmic growth phase. At this point, the culture has an abundance 
of healthy cells and ample nutrients remaining in the media for continued growth. The cultures 
were then induced with 0.5 mM IPTG and moved to a 16 oC overnight shaker. IPTG triggers a 
change in the conformation of the lac repressor on the lac operon in the BL21 DE3 genome, 
causing it to dissociate and allow binding of the T7 RNA polymerase. This commences 
expression of the TEM-1 β-lactamase.  Expression was tested at both 16 oC and 30 oC to 
establish the best temperature for correct protein folding. Expression at 16 oC was ultimately 
found to provide more homogeneous and higher quantity TEM-1 β-lactamase than at 30 oC. 
The overnight cultures were centrifuged down, the bacteria pellets isolated and lysed to release 
the TEM-1 β-lactamase into solution. 
 
2.12 Extraction and purification of TEM-1 β-lactamase 
 I acknowledge Dr. Bill McKinstry for assistance in extracting the β-lactamase and 
Lesley Pearce for guidance in protein purification. TEM-1 β-lactamase was extracted from the 
bacterial cell pellets and then purified from the other bacterial proteins. Cell lysis can be 
achieved using mechanical techniques, such as sonication and cell crushing using a French 
press, or non-mechanical techniques like alkaline chemical lysis or enzymatic lysis (2.12.1). 
Combinations of mechanical and non-mechanical techniques were used here to extract the 
TEM-1 β-lactamase from the pellets (2.12.2). After the bacterial cells were lysed, the expressed 
TEM-1 β-lactamase was purified using immobilized metal affinity chromatography (IMAC). 
Adding the cell lysate to the column leads to the TEM-1 β-lactamase becoming immobilised 
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through binding of the His tag to the nickel column matrix; this step removes most non-His 
tagged proteins. Further purification by gel filtration chromatography was performed to 
separate the homogenous TEM-1 β-lactamase from protein aggregate mixtures (2.12.4). 
 
2.12.1 Chemical and enzymatic extraction 
 Pellets obtained in 2.11 were lysed on ice using chemical and enzymatic lysis buffer 
(PBS with 0.02% NaN3, 150 mM NaCl, 2 mM MgCl2, 10 mM imidazole, 0.5 mg/mL lysozyme, 
5 ul benzonase, 1 mM PMSF and 3 tablets of protease inhibitor pellets) in a ratio of 10 mL of 
lysis buffer to 1 gram of cells. Sodium azide (0.02%) was included to prevent microbial 
contamination and sodium chloride was used to raise the ionic strength of the buffer.  This 
helps to break down protein complexes and causes cells to ‘implode’ due to the increased 
external osmotic pressure.  Lysozyme was used to break up the cell wall and benzonase and 
MgCl2 were used to separate the DNA and RNA from the cells and degrade them. PMSF and 
a cocktail of protease inhibitors were used to inhibit the functions of proteases and protect the 
TEM-1 β-lactamase. A low concentration of imidazole was added to prevent the His tag from 
forming a complex with adventitious metal ions. The pellet in the lysis buffer was stirred at 
4 oC until the sample became a homogeneous mixture, after which the samples were treated 
using the cell crusher or sonicator. 
 
2.12.2 Cell crushing and sonication 
Occasionally, cells are not broken down by chemical or enzymatic treatment and 
require further mechanical action using a cell crusher or sonicator. Cell crushing involves 
passing cells through a French press at high pressure (15000 to 16000 psi) multiple times, 
where the shear stresses cause the cells to rupture. The French press can handle large amounts 
of cellular matter; however, it is time-consuming and is plagued by blockages in valve that are 
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difficult to clean. The French press, EmulsiFlex C5 high pressure homogeniser is covered with 
ice to keep it cool.  Alternatively, a sonicator S4000 fitted with a 20 kHz converter and ½ inch 
probe with a replaceable tip, can be used to disrupt the membranes of cells and break them 
open. The cell matter was placed in the sonicator vessel and sonicated using a titanium probe. 
The vessel needed to be kept on ice as sonication generates heat. Rest phases were used to 
allow the vessel to cool down between the pulses. The sonicator can only handle small volumes 
of cellular matter in one cycle of pulse and rest and constant use can cause overheating and 
damage to the proteins. Both methods were trialled for obtaining cell lysates for the protein 
purification steps. 
 
2.12.3 Immobilized metal affinity chromatography 
 The lysed samples from 2.12.2 were centrifuged and separated into supernatant and 
pellet. A 5 mL His-Trap column was attached to a protein purification instrument (Bio-Rad 
Profinia™ Affinity Chromatography Protein Purification System) and the supernatant was 
loaded onto the column. The initial binding phase adheres the TEM-1 β-lactamase and some 
non-specific proteins to the nickel matrix in the His-Trap column, while non-His-tagged 
proteins are collected in the flowthrough. Two washes were performed using PBS with 0.02% 
NaN3, 150 mM NaCl, 10 mM imidazole followed by PBS with 0.02% NaN3, 150 mM NaCl, 
20 mM imidazole to remove any non-specific binding proteins from the column. The TEM-1 
β-lactamase was then eluted with PBS containing 0.02% NaN3, 150 mM NaCl and 250 mM 





Figure 13. Chromatogram from the IMAC purification of TEM-1 β-lactamase from crude cell 
lysate supernatant. Green lines show the UV intensity at 280 nm and pink lines show 
conductivity. 1A, 1B, 1C and 1D indicate the collected sample tubes. 
 
 During the first 10 minutes, there was a small jump in the conductivity as the system is 
switched to binding buffer. There is a small jump in the UV signal as any previous proteins 
and impurities are washed out. The UV intensity at A280 nm then rises sharply (tube 1A) and 
becomes saturated at 1.2. This is caused by the large amount of unbound protein flowing off 
the column. At this stage, the His-tagged and other proteins with affinity for the nickel column 
matrix were bound and all other proteins had eluted into tube 1A. In tube 1B, the UV decreases 
back to baseline as all the proteins that were not immobilised on the nickel matrix had exited 
the column. Tube 1C shows a small increase in the UV signal, possibly due to proteins with 
low affinity for the nickel matrix are eluted. A large peak (tube 1D) was collected that appeared 
to correspond to the TEM-1 β-lactamase. The crude lysate and each collected tube were 
analysed by SDS-PAGE gel electrophoresis to determine whether the IMAC purification had 















Figure 14. SDS-gel of samples collected from the IMAC purification of TEM-1 β-lactamase. 
Lane 1 = SeeBlue 2 standard protein ladder. Lane 2 = crude cell lysate s. Lanes 3 and 4 = lysate 
supernatant and pellet, respectively. Lane 5 = flowthrough samples from IMAC (tube 1A). 
Lane 6 and 7 = tubes 1B and 1C, respectively. Lane 8 = tube 1D containing the TEM-1 β-
lactamase.  
The cell lysate (Lane 2) and supernatant fraction (Lane 3) showed similar proteins, 
including a concentrated band above the 28 kDa marker. The pellet fraction (Lane 4) showed 
almost no protein compared to the lysate and supernatant, suggesting that the lysis buffer and 
the cell crusher had successfully extracted all of the cellular proteins, including the expressed 
TEM-1 β-lactamase, and that these proteins were soluble. The flowthrough (Fraction 1A) 
showed a similar pattern of proteins as the lysate and supernatant fractions, except the 
concentrated band above 28 kDa was not visible, suggesting the HisTrap column had trapped 
the His-tagged TEM-1 β-lactamase. The wash 1 fraction (Fraction 1B) and wash 2 fraction 
(Fraction 1C) showed faint bands above the 28 kDa marker, suggesting some weaker binding 
N-His tagged protein had dissociated from the column. This elution fraction 1D showed only 
a single concentrated band above the 28 kDa marker, consistent with the His-tagged TEM-1 β-
lactamase. 
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 The elution fraction 1D was collected and its protein concentration measured using a 
Nanodrop spectrophotometer (2.4), with elution buffer serving as the blank, (extinction 
coefficient: 28,085, MW: 29,410 Da). The concentration of 1D was determined to be 1.2 
mg/mL. Due to the volume of the elution fraction being greater than the maximum loading 
capacity on the gel filtration column, elution fraction 1D was concentrated using an Amicon® 
Ultra-15 10,000 MW cut-off spin concentrator. Sequential concentration of 5 mL aliquots 
reduced the volume from 110 mL to 30 mL.  Nanodrop concentration measurements at 280 nm 
using PBS as a blank were performed to determine if any TEM-1 β-lactamase had been lost 
during the protein concentration step. The initial amount of  pooled TEM-1 β-lactamase eluted 
from the multiple runs of IMAC columns were 196 mg at a concentration of 3.76 mg/mL. The 
pooled TEM-1 β-lactamase obtained after final concentration was 187 mg at 6.23 mg/mL. This 
indicated that most of the TEM-1 β-lactamase had been retained in solution and not precipitated 
during concentration. The concentrated TEM-1 β-lactamase samples were advanced to final 
purification by gel filtration chromatography. 
 
2.12.4 Gel filtration chromatography 
 Gel filtration chromatography (GFC) is routinely used to separate protein mixtures 
based on molecular size. Small proteins can strongly interact with the matrix as they are small 
enough to enter the pores of the gel, slowing their migration compared to larger proteins. 
Proteins therefore elute in order of decreasing molecular weight, that is, larger proteins elute 
earlier from the column and smaller proteins elute later. GFC can also separate protein 
aggregates from their monomeric forms, as protein aggregates have a higher molecular weight. 
 GFC was used as the final step in purifying the TEM-1 β-lactamase and to ensure that 
the protein isolated is a homogenous monomer. The concentrated samples were loaded in 4 
cycles of 7.5 mL aliquots onto a Superdex 200, 26/60 column attached to an AKTA Pure 
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chromatography instrument.  The elution buffer was PBS that had been 0.22 µm sterile filtered 
and 1 mL fractions were collected in 96 deep-well plates. Elution of proteins was monitored at 




Figure 15. Gel filtration chromatogram of TEM-1 β-lactamase purification. 
 The chromatogram is zoomed between 80 - 280 mL where all the proteins eluted. Conductivity 
(Cond) is shown in orange. Collected fractions1E and 1F corresponded to protein aggregates. 
1G was the intermediate between the protein aggregates and the monomeric TEM-1 β-
lactamase (1H). 
 The eluted proteins were collected in tubes labelled 1E, 1F, 1G and 1H. A drop in 
conductivity was shown at retention time of 110 mL indicating the salts from the injected 
sample were being eluted. The main peak was located between retention volumes 210-255 mL, 
which was collected in tube 1H. It was likely that the peaks designated as 1E and 1F were 
aggregated and dimerised protein, respectively. Tube 1G corresponded to the eluent between 
the main protein peak and the dimerised protein peak. An SDS-PAGE gel (Figure 16) run on 







protein purity and confirmation of size. All sample concentration were measured using the 
















Figure 16. SDS-PAGE gel of samples collected from the first GFC run. Lane 1 = SeeBlue 2 
MW Ladder. Lanes 2-4 = every 5th sample in Tube 1E. Lanes 5 and 6 = samples from Tube 1F. 
Lanes 7-12 = samples from Tube 1H. 
 Lane 1 contained the commercial See Blue 2 protein MW ladder. Lanes 2-4 
corresponded to every 5th sample in tube 1E. Lanes 5 and 6 contained samples from 1F. Lanes 
7-12 came from tube 1H. 1G was not run in the gel due to its low protein content. Each lane 
showed a protein band at around the 28 kDa MW marker, with the bands becoming more 
concentrated with each progressing fraction. Lanes 2-5 indicate that the samples loaded 
contained protein around the 62 kDa MW marker and above, suggesting that larger proteins or 
aggregates were eluting with the TEM-1 β-lactamase. Moving from left to right across the SDS 
gel, these other proteins or aggregates diminished in intensity until only the pure protein band 
at 28 kDa remained.  
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In comparing Figures 15 and 16, tube 1H contained most of the protein, as evidenced 
by the high UV absorbance at 280 nm. Protein absorption at this wavelength is caused by the 
aromatic amino acids, tyrosine, tryptophan and phenylalanine. The gel lanes corresponding to 
tube 1H confirmed it contained almost pure protein with the correct mass of 28 kDa. Fractions 
from 1H were next subjected to mass spectrometry to confirm the correct mass of the TEM-1 
β-lactamase. 
 
2.12.5 Mass spectrometry 
 MALDI-TOF MS analysis was performed on the protein samples from tube 1H by Dr. 




Figure 17. MALDI-TOF mass spectrum of protein (1 mg/mL) contained from tube 1H. Figure 
provided by Dr Tom Nebl. 
 
 From Table 1, the expected molecular weight of the His-tagged TEM-1 β-lactamase 
was 31,876.11 Da. The deconvoluted MALDI-TOF mass spectrum (Figure 17) showed a major 
peak corresponding to a protein of 31,876.0 Da. This molecular weight was identical to the 
theoretical weight, confirming that tube 1H contained the desired, His-tagged TEM-1 β-
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lactamase.  A small peak at around 32,053.1 Da indicated the possible presence of a small 
amount of gluconoylated protein and addition of 80.4 Da suggests potentially further 
phosphorylation.  
 
2.13 TEM-1 β-lactamase: stability and activity studies 
 After successfully cloning, expressing and purifying the TEM-1 β-lactamase, the next 
step was to determine if the protein had suitable enzymatic activity and stability.  Differential 
Scanning Fluorimetry (DSF) studies, performed by Dr. Janet Newman from the Collaborative 
Crystallisation Centre at CSIRO, were performed to establish the stability of the TEM-1 β-
lactamase under a range of pH and buffer conditions. DSF measures unfolding of proteins from 
the changes in fluorescence that occur as the temperature is increased.  The melting temperature 
(Tm) is used to indicate when half of the protein has unfolded, with higher Tm corresponding 





Figure 18. Melting temperature (Tm) of purified TEM-1 β-lactamase under a range of pH and 
buffer conditions. Study performed and figure provided by Dr. Janet Newman, CSIRO).  
 
 These experiments helped to understand the stability of the protein over the pH range 
5.0-9.0 under low NaCl (50 mM) and high NaCl (200 mM) conditions in various buffers. The 
Tm of the β-lactamase in PBS was measured at 37.21 oC. Figure 18 shows that the Tm under 
all conditions was higher than in PBS, and that the enzyme is more stable at lower pH and that 
salt concentration has minimal effects on stability. 
 The catalytic activity of β-lactamases can be measured by reacting the enzyme with the 
chromogenic cephalosporin substrate nitrocefin, which gives rise to a coloured product when 
the β-lactam ring opens (Scheme 6). A nitrocefin assay was performed on the TEM-1 β-
lactamase according to the guidelines provided by the manufacturer (Biovision) against a 
standard curve (Appendix 3). The β-lactamase was found to show an activity of 3600 U. One 
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unit (U) of TEM-one β-lactamase activity is the amount of enzyme that generates 1 µmol of 
nitrocefin per minute at pH 7.0 at 25°C. 
 
 
Scheme 6. Ring opening of nitrocefin by β-lactamases causes a colour change from yellow to 
red that is used to quantify enzyme activity. 
 
2.14 Cleavage of the His-TEV tag 
I acknowledge Dr. Bill McKinstry for assistance in cleaving the TEM-1 β-lactamase 
His tag. The final step in preparing the β-lactamase prior to use in bioconjugation studies was 
removal of the His-TEV purification tag. This was achieved by incubating the His-TEV-β-
lactamase with His-TEV protease in the presence of the reducing agent dithiothreitol (DTT) 
overnight in a refrigerator. DTT was required to activate the His-TEV protease. The cleaved 
β-lactamase was purified from the His tag and the protease using an IMAC column. The 
mixture was added to the IMAC column and the cleaved β-lactamase was collected in the 
flowthrough. PBS with increasing concentrations of imidazole (10 mM, 20 mM, 250 mM) was 
then used to subsequently wash the other components from the column. SDS-PAGE gel and 
Western blot analysis were used to confirm removal of the His-TEV tag. The cleavage was run 




















Figure 19. (A) SDS-PAGE gel and (B) Western blot from the His-TEV cleavage reaction.  
Lane 1 = SeeBlue 2 MW ladder. Lane 2 = uncleaved His-TEV-β-lactamase. Lane 3 = TEV 
protease. Lane 4 = flowthrough for batch 1. Lane 5 first wash for batch 1. Lane 6 = second 
wash from batch 1. Lane 7 = elution for batch 1.  Lane 8 = flowthrough for batch 2. Lane 9 = 
first wash for batch 2. Lane 10 = second wash for batch 2. Lane 11 = elution for batch 2.  
1        2       3        4        5         6         7        8        9        10     11    
1      2       3        4       5        6         7        8       9       10     11    
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 The SDS-PAGE gel for the cleavage reaction showed that the protein band in the 
flowthrough and washes (lanes 3-6) were different from the His-tagged β-lactamase control 
(lane 2). This was expected as loss of the tag (2 kDa) causes a decrease in the protein’s 
molecular weight, making it run faster through the gel. The corresponding Western blot 
depicted a concentrated band for the His-tagged enzyme (lane 2), and a concentrated band in 
the elution sample, suggesting a large amount of uncleaved His-tagged β-lactamase was still 
present. The N-His tag on its own is only around 2 kDa and does not show on the Western Blot. 
The Western blot also showed a negative result for wash 1, which had an equivalent strong 
band in the SDS-PAGE-gel. This result suggested that wash 1 contained the cleaved β-
lactamase, while the uncleaved β-lactamase had come through in the flowthrough. In the 
second batch, a band with the correct size occurred in lane 8 in the SDS-PAGE gel with no 
equivalent signal present in the Western blot, indicating that the cleaved β-lactamase was 
present in the flowthrough this time. Lane 9 showed a band at 29 kDa that had an equivalent 
band in the Western blot, corresponding to the His-TEV protease. The reasons for the 
anomalous elution profiles are unknown but were likely due to human error. Nevertheless, 
samples from Lanes 4 and 8 containing the pure, His-tag cleaved TEM-1 β-lactamase were 
buffer-exchanged into PBS using Amicon®-15 10,000 MW cut off spin filters and mass spectra 







Figure 20. MALDI-TOF mass spectrum of the cleaved TEM-1 β-lactamase from: (A) Lane 4 
and (B) Lane 8. Experiment performed and figure provided by Dr Tom Nebl, CSIRO. 
The theoretical molecular weight of the TEM-1 β-lactamase after removal of the tag 
was 29410.47 Da (calculated using ProtParam). The mass spectra from the two matches, 
showed closely matching peaks at 29408.7 and 29410.0, respectively, confirming that the target 
TEM-1 β-lactamase had been successfully isolated. The pure protein was stored in PBS buffer 
at 2.39 mg/mL in the fridge (4 oC). Enzyme activity was not performed on the cleaved TEM-1 
β-lactamase due to time restriction. It is known that the tag was on the N-terminus and away 




 A TEM-1 β-lactamase was designed and cloned in E. coli. Expression of the enzyme 
occurred at 16 oC overnight with induction by IPTG. Purification of the enzyme was achieved 
by lysing the cells using a combination of chemical and mechanical techniques, followed by 
sequential IMAC and GFC columns. Mass spectrometry confirmed that the expressed protein 
had the correct molecular weight. The DSF assay showed that the enzyme is more stable at 
lower pH, which was important for planning bioconjugation strategies (Chapter 3) that would 
















Chapter 3: Bioconjugation of TEM-1 
β –lactamase to the model antibody 




3.1 Introduction  
 Bioconjugation is the chemical coupling of two molecules together via a covalent 
linker, with at least one of the molecules being a biomolecule, such as a protein. For this study, 
the TEM-1 β-lactamase was to be conjugated to the antibody fragment Fab' 528.  This particular 
antibody fragment was chosen for this work as a model protein and representative of a range 
of possible antibody fragments and, more generally, cysteine-containing proteins that are 
amenable to thio-based conjugation chemistry. The antibody fragment Fab' 528 was derived 
from the monoclonal IgG antibody, referred to as 528. Fab' 528 has been shown to reduce 
expression of Epidermal Growth Factor Receptor (EGFR) in malignant human cell lines.106 
Fab' 528 is routinely prepared by reduction of 528-F(ab')2 using the mild reducing agent, tris(2-
carboxyethyl) phosphine (TCEP). Bioconjugation reactions can utilise the nucleophilic thiol 
groups on Fab' 528 fragment that are solvent exposed after the reduction (Figure 21).  
 
 
Figure 21.  Disulfide reduction of 528-F(ab′)2 with TCEP to give Fab′ 528.  Two solvent 
accessible thiols are revealed after reduction at the hinge region of the antibody fragment and 
can be used in bioconjugation reactions.  
 
 The strategy for conjugating the Fab' 528 fragment to the TEM-1 β-lactamase involved 
use of the small water soluble crosslinker sulfo-succinimidyl-(N-maleimidomethyl) 




Scheme 7. Conjugation chemistry plan. TEM-1 β-lactamase is first attached to the sulfo-
SMCC- linker via amide coupling and the Fab' 528 fragment is subsequently appended using 
thiol-maleimide chemistry, forcing the β-lactamase-Fab' 528 conjugate. 
 Sulfo-SMCC is a commercially available heterofunctional cross-linker that is 
commonly used in bioconjugation chemistry. In general, bioconjugation using this crosslinker 
does not give rise to site-specific protein modification. This is because the N-
hydroxysuccinimide (NHS) ester group of sulfo-SMCC can form amide bonds with any 
solvent-exposed amines on a protein, such as those on surface lysines and, in some 
circumstances, the N-terminal primary amino group. Similarly, the maleimide group can react 
with the thiol groups on any of a biomolecule’s solvent-exposed cysteine residues. The sulfo-
SMCC group is a relatively short linker at 8.3 Å in length. The hydrophilic sulfonate group 
enhances aqueous solubility of sulfo-SMCC, allowing the compound to be soluble at 
concentrations up to 10 mM in water or buffer. 
 The TEM-1 β-lactamase contains no solvent-exposed cysteines. and can therefore only 
react with the NHS group of sulfo-SMCC via its amino groups. TEM-1 β-lactamase contains 
two cysteines that forms a disulfide bond located in the centre of the enzyme.102 The Fab' 528 
antibody fragment, when first reduced, contains two solvent accessible cysteines. Thus, the 
Fab' 528 can be conjugated via these hinge region exposed thiols to the maleimide group of the 
sulfo-SMCC crosslinker. The sulfo-SMCC was thus reacted first with the TEM-1 β-lactamase 
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via the NHS group and the functionalised β-lactamase subsequently conjugated to Fab' 528 via 
the maleimide group. This conjugation method can lead to heterogenous products as the NHS 
active ester can react with any of the solvent assemble lysine amine residues on the TEM-1 β-
lactamase surface and the maleimide group can react with either of the two exposed thiols on 
the Fab' 528. Site-specific bioconjugation ( 5.2.1) can be performed to prevent this potential 
issue. 
Solvent and pH were important considerations in the bioconjugation reactions. NHS 
esters react with protein amines at pH 7-9 to form stable amide bonds. The maleimide group 
reacts with protein thiol groups at pH 6.5-7.5, to form stable thioether bonds. In section 2.13, 
TEM-1 β-lactamase was shown to have good stability across the pH range 5.0-7.0 and in PBS 
buffer. Previous studies from the Williams research group at CSIRO described conjugation of 
the Fab' 528 fragment to PEGylated doxorubicin constructs in PBS at pH 7.2.106  
 
3.2 Molar ratios in the reaction of TEM-1 β-lactamase with sulfo-SMCC 
Experiments were performed to determine the optimal number of molar equivalents of 
sulfo-SMCC required for one-to-one attachment of the sulfo-SMCC crosslinker to the TEM-1 
β-lactamase. Ratios of 1:1, 1:5 and 1:10 TEM-1 β-lactamase (2.39 ng/mL) to sulfo-SMCC 
(dissolved in water to give 4.36 mg/mL) were reacted at room temperature for 1-2 hours before 
passing each through a gel filtration column (S200 10/300 increase) using PBS as eluent 
(2.12.4).  Initial ratio experiments were performed with 4 nanomoles of TEM-1 β-lactamases.  




Figure 22. Gel filtration chromatograms of crude reaction mixtures obtained during molar ratio 
experiments with TEM-1 β-lactamase and sulfo-SMCC. 
 
 The overlaid chromatograms of the crude reaction mixtures showed that in all 
experiments the protein peak appeared to remain unchanged relative to the unreacted control 
TEM-β-lactamase sample (purple), which eluted at 17 mL. Excess and unreacted sulfo-SMCC 
and the NHS leaving group eluted later from the column, giving a peak at 20 mL. A small 
shoulder in the protein peak (~16 mL) suggested that some of the β-lactamase may have 
become aggregated. Fractions collected across the 17 mL peak were pooled, concentrated and 
analysed by mass spectrometry to determine if the sulfo-SMCC group had been conjugated to 
the protein.  
The molecular weight of the His tag-cleaved TEM-1 β-lactamase is 29,410.47 Da. 
When one sulfo-SMCC molecule reacts via its NHS ester with a protein amino group, the 
molecular weight increases by 218 Da. The mass spectra indicated that the molar ratios of 1:5 
and 1:10 (protein: crosslinker) both led to addition of one sulfo-SMCC linker to the TEM-1 β-
lactamase (Appendix 4-6). All subsequent reactions were therefore performed using a protein: 
crosslinker molar ratio of 1:10. After performing the reactions, the linker-installed protein was 
purified on a 1 mL HiTrap desalting column to remove the excess SMCC/NHS by-products. 
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The TEM-1 β-lactamase-SMCC was used immediately with the Fab' 528 to avoid hydrolysis 
of the maleimide. 
 
3.3 Reduction of 528-F(ab′)2 to Fab′ 528 
 I thank Dr. Judith Scoble at CSIRO for providing me with the 528-F(ab')2 antibody. 
The Fab' 528 antibody fragment was obtained by routine reduction of the complete 528-F(ab)'2 
antibody using TCEP (Figure 21). The concentration of TCEP used to selectively reduce the 
solvent exposed, hinge region disulfides, needed to be controlled so that the intramolecular 
disulfide bonds between the light and heavy chains of the Fab' 528 fragment were not also 
reduced. The molar ratio of 528-F(ab)'2 to TCEP used in the reaction was trialled from 1 molar 
equivalent of the reducing reagent to 100-fold excess. It was found that a 100-fold excess of 
TCEP provided the largest amount of Fab' 528 and did not lead to over-reduction of the 
intramolecular disulfide bonds. Using this ratio, 528-F(ab)'2 was reacted with TCEP for 1 hour 







Figure 23. Representative gel filtration chromatogram for purification of the Fab' 528 antibody 
fragment following reduction of 528-F(ab’)2 with TCEP. 
 
 
 The GFC showed that three main A280 nm peaks eluted from the GFC column after 
loading the crude reaction mixture. The peak at 15 mL corresponded to unreacted (or re-
oxidised) 528-F(ab)'2. The major peak at 17 mL corresponded to the reduced Fab' 528 fragment 
and the peak at 21 mL was due to salts and small molecules, such as TCEP. Fractions were 
collected across the peak at 17 mL and pooled. Protein MW standards eluting at 17 mL are 
known to be around 50 kDa, corresponding to the MW of Fab' 528 (MW = 49527.51 g/mol). 
The pooled Fab' 528 fractions were quickly submitted to reactions with the TEM-1 β-
lactamase-SMCC conjugate obtained in 3.2 because over time the Fab' 528 slowly air-oxidises 
back to 528-F(ab)'2. 
 
3.4 Conjugation of the TEM-1 β-lactamase-sulfo-SMCC linker conjugate to Fab′ 528 
 The concentrated TEM-1 β-lactamase-sulfo-SMCC linker conjugate and pooled Fab' 
528 solutions were mixed together to react the maleimide group of sulfo-SMCC with the 
reduced hinge thiols of the Fab' 528 antibody fragment. The maleimide group on the sulfo-
SMCC linker can also hydrolyse in water, making it unreactive towards crosslinking. Michael 
addition of protein thiols to the maleimide leads to stable conjugates.107 Conditions for the 
bioconjugation reaction were explored using incubation periods of 1-24 hours at two 
temperatures; 25 and 4 oC. Reactions stirred for 2 hours at room temperature followed by 
overnight at 4 oC were found to provide reasonable yields of conjugation products. The final 
target TEM-1 β-lactamase-Fab' 528 conjugate was isolated from reaction mixtures and purified 





Figure 24. Gel filtration chromatogram from the isolation of TEM-1 β-lactamase-sulfo-
SMCC-Fab′ 528 from the maleimide conjugation reaction. 
  
 The GFC showed two major peaks at 14.6 mL and 17 mL and a very broad peak from 
9-14 mL. The samples were pooled within the indicated fraction lines and collected into tubes 
labelled 2A-2E. Fractions 2A-2D were concentrated and analysed using SDS-PAGE gel 












 1           2         3          4          5         
 
2A 2B 2C 2D 2E 
1         2           3          4           5 
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Figure 25. SDS-PAGE gel of the concentrated fractions from the GFC purification of the β-
lactamase-sulfo-SMCC-Fab′ 528 conjugate. Lane 1 = SeeBlue 2 MW Protein Ladder, Lane 2 
= Tube 2A, Lane 3 = 2B, Lane 4 = 2C, Lane 5 = 2D. 
 
 The gel showed that no protein was present in lanes 2 and 3 (Coomassie blue detection). 
The high A280 nm absorption observed for tubes 2A and 2B suggested that protein aggregates 
may have been forming during the purification. Lane 4 showed a protein band between the 62 
kDa and 98 kDa MW markers (red rectangle), consistent with the theoretical weight of the 
conjugate (79,174.23 Da). Lane 5 showed a protein band around the 28 kDa marker, consistent 
with the unconjugated TEM-1 β-lactamase-SMCC linker (MW = 29 626.5 Da). A MALDI-
TOF mass spectrum was acquired on the tube 2C fractions and a sample was analysed by to 
SDS-PAGE gel electrophoresis to confirm that they contained the desired conjugate. 
During SDS-PAGE-gel electrophoresis run under reducing conditions, all intra- and 
inter-molecular disulfide bonds are reduced. As the free thiol used for the conjugation was 
located on the heavy chain of the Fab' 528 fragment (Figure 25), reduction of the disulfide bond 
between the light (Vl) and heavy (Vh) chains would yield the antibody fragment Vl chain and 
the Vh chain conjugated to the TEM-1 β-lactamase-SMCC. Both Fab' 528 fragments (Vl and 
Vh) have approximate molecular weights of 20-25 kDa. Thus, unreacted light chain should run 
at around 20-25 kDa relative to the SDS-PAGE gel MW markers. When conjugated to the 29 
kDa β-lactamase, the heavy chain should run at around 54 kDa. 
 
3.5 Mass spectral analysis of the TEM-1 β-lactamase-sulfo-SMCC-Fab' 528 conjugate 
 A MALDI-TOF mass spectrum of the conjugate was acquired by Dr. Tom Nebl in the 
CSIRO mass spectrometry lab. The spectrum (Figure 26) showed a peak at 79,139.6 Da (after 
deconvolution), which matched the theoretical molecular weight of the β-lactamase-sulfo-





Figure 26. Deconvoluted MALDI-TOF mass spectrum of the TEM-1 β-lactamase-SMCC-Fab′ 
528 conjugate. The spectrum was acquired, and the figure provided by Dr. Tom Nebl, CSIRO. 
 
3.6 Reducing SDS-PAGE gel electrophoresis of the TEM-1 β-lactamase-sulfo-SMCC-
Fab′ 528 conjugate 
 SDS-PAGE gel analysis was performed under reducing and non-reducing conditions 
on the TEM-1 β-lactamase-SMCC-Fab' 528 conjugate sample obtained from the pooled, 
concentrated tube 2C fractions (Figure 24). Reducing conditions were achieved by addition of 

















Figure 27. SDS-PAGE gel of the TEM-1 β-lactamase-SMCC-Fab' 528 conjugate run under 
non-reducing and reducing conditions.  Lane 1 = SeeBlue 2 protein ladder. Lanes 2-4 = non-
reduced TEM-1 β-lactamase, 528-F(ab')2 and TEM-1 β-lactamase-SMCC-Fab' 528 conjugate, 
respectively. Lane 6, 7, 8 = the same respective samples under TCEP reducing conditions.  
 
 Lane 2 in the gel showed the expected band at approximately 28 kDa for the His-tag 
cleaved TEM-1 β-lactamase control (MW = 29410.47 g/mol). The band did not change under 
reducing conditions (Lane 6). Lane 3 showed one major band for the 528-F(ab')2 antibody 
control (MW = 99055.02 g/mol) at around 98 kDa and Lane 4 showed one major band for the 
conjugate (MW = 79174.23 g/mol) at around 75 kDa. Reduction of the 528-F(ab')2 antibody 
with TCEP produced two bands at around 50 kDa and 25 kDa (Lane 7), consistent with 
cleavage to the Vh and Vl fragments. TCEP reduction of the conjugate produced a light chain 
Vl band at ~25 kDa and a ~50 kDa band for the TEM-1 β-lactamase-SMCC-Vh fragment (Lane 
8). The combination of mass spectral and SDS-PAGE gel data confirmed that the desired TEM-
1 β-lactamase-sulfo-SMCC-Fab' 528 conjugate had been obtained. 
 When tested using the nitrocefin assay (2.13), the TEM-1 β-lactamase-sulfo-SMCC-
Fab' 528 conjugate showed enzymatic activity of 2.5 kU. This represented only 69.4% of the 
activity of the (His-tagged) TEM-1 β-lactamase predecessor (3.6 kU). It is likely that the non-
site-specific nature of the conjugation reaction between sulfo-SMCC and the TEM-1 β-
lactamase (i.e. non-selective amide coupling to solvent exposed lysines/N-terminus) were 
responsible for the loss of activity, possibly through steric blocking of substrate access to the 
active site.  At this stage, the expressed TEM-1 β-lactamase and TEM-1 β-lactamase-sulfo-






















Chapter 4: Synthesis of DEA-C3D 






 The next part of the work aimed to test the expressed TEM-1 β-lactamase and 
synthesised TEM-1 β-lactamase-sulfo-SMCC-Fab' 528 conjugate for their ability to trigger NO 
release from C3Ds. The Kelso Group at UOW have synthesised several C3Ds over the past 
decade and demonstrated that they release NO when treated with β-lactamases. These studies 
have focussed on the antibacterial and antibiofilm properties of the compounds since NO acts 
as a biofilm disperser.78,79,108,109 None of these previous studies have investigated NO release 
from C3Ds in the presence of a β-lactamase that had been conjugated to another protein. This 
chapter describes the re-synthesis of DEA-C3D 1, a cephalosporin-3'-diazeniumdiolate that 
incorporates the diethylaminodiazeniumdiolate (DEA-NONOate). This particular C3D was 
chosen for its rapid NO release properties in the presence of β-lactamases (half-life = 2 
minutes).110 
 The synthetic approach to 1 is depicted in Scheme 8. The first step involves freshly 
preparing the sodium diazeniumdiolate salt DEA-NONOate 2. This salt is then reacted with 
the commercially available cephalosporin PMB-ester 3 via a sodium iodide-promoted 
(Finkelstein) halogen substitution reaction to give the penultimate product 4. PMB-ester 
deprotection of 4 gives the target compound DEA-C3D 1. The mechanism of how the TEM-1 
β-lactamase and β-lactamase-sulfo-SMCC-Fab' 528 conjugate would be expected to generate 




Scheme 8. Planned synthesis of DEA-C3D 1. 
 
4.1 Synthesis of DEA-NONOate 2 
 I acknowledge Dr Ardeshir Rineh for assisting in the synthesis of DEA-NONOate. The 
sodium salt DEA-NONOate 2 was synthesised according to the method reported by the Kelso 
group.78 The diazeniumdiolate needed to be freshly prepared prior to reaction with 
cephalosporin 3 as it is unstable and quickly degrades at room temperature or in the freezer. 
The reaction involved adding anhydrous diethylamine (DEA), NaOMe, MeOH and Et2O to a 
sealed Parr-Knorr vessel and shaking under a constant pressure of NO gas (50 psi) for 3 days. 
The precipitate was collected by filtration (under a stream of dry argon), washed with ether and 
dried under vacuum. The white powder was stored under argon in a sealed dry flask wrapped 
in foil in the freezer and used within 2-3 days. This reaction was performed once on a 7 g scale 
and produced DEA-NONOate 2 in 25% yield. The mechanism of this reaction involves 
nucleophile attack of the DEA onto the electron deficient NO radical) to form the N-N bond. 
Radical-radical coupling followed by hydrogen atom transfer and final hydrogen atom 





Scheme 9. Mechanism for the formation of DEA-NONOate 2 in the reaction of diethylamine 
with NO(g) under pressure in sodium methoxide/methanol solution. 
 
 
 Secondary amine diazeniumdiolates are powerful and versatile NO donors under 
physiological conditions.7 A wide range of secondary amines have been used for preparing 
diazeniumdiolates that show NO release half-lives varying from seconds to days. The NO-
donor DEA-NONOate 2 becomes stable when coupled to cephalosporins and does not release 
NO.80 The diazene double bond can theoretically adopt both the syn (Z) and anti (E) 
configurations, however, the reaction produces only the more thermodynamically stable Z 
isomer. Photochemical studies suggest that O-linked diazeniumdiolates (e.g. DEA-C3D) can 
photo decompose, thus all reactions must be performed in flasks covered in foil.64 In the 
presence of light the compound could decompose to form NO and the secondary amine. Two 
pathways have been suggested for O-linked diazeniumdiolate decomposition (shown in 





Scheme 10. Decomposition pathways for O-benzyl-DEA-NONOate in the presence of light. 
 
 
 In the presence of light, the minor pathway (5 %) involves cleavage at the N-O bond, 
forming nitrous oxide (N2O), as well as aminyl and alkoxyl radicals that ultimately form 
amines, aldehydes and alcohols. The major reaction pathway (95%) involves photochemical 
cleavage of the N=N bond to form the nitrosamine and an oxygen-substituted nitrene. The 
oxynitrene structure was inferred from the production of abundant oxime, occurring via 
rearrangement of the oxynitrene to a C-nitroso compound and subsequent tautomerization to 
the stable oxime.111 
 
4.2 Synthesis of PMB-protected DEA-C3D 4 
 I acknowledge Dr Ardeshir Rineh for assisting in the synthesis of compound 4. The 
reaction involved O-alkylation of DEA-NONOate 2 with the commercially available 
cephalosporin precursor 3. It is well known that alkylation occurs on the terminal oxygen of 
diazeniumdiolates.7 The Kelso group identified that direct alkylation of sodium 
diazeniumdiolates with 3 does not produce the O-alkylated product  and that an in situ 
Finkelstein reaction is required to first convert the chloride to the more reactive iodide.78,80 The 





Scheme 11. Mechanism for the formation of PMB-protected DEA-C3D 4. 
 
 
As with all cephalosporins, C3D esters like 3 and the product 4 are prone to double 
bond migration during 3'-substitution reactions involving basic nucleophiles, leading to 
variable formation of the 2 isomer.112 This isomer is unable to undergo the conjugate 
elimination reaction and release the diazeniumdiolate (and hence NO) after β-lactam ring 
opening. Due to the difficulties in separating this isomer from the desired 3 isomer, 
isomerisation needed to be avoided during the reaction. To lower the likelihood of 2 isomer 
formation, the Finkelstein/diazeniumdiolate substitution reaction was performed under 
scrupulously anhydrous conditions under argon in dry acetone and the product 4 was stored in 
the freezer at -20 oC. 
The alkylation reaction was performed four times on 0.5-1.0 g scale using one molar 
equivalent of DEA-NONOate 2 at room temperature in each case. Yields of 20-24% of 4 were 
obtained after silica gel column chromatography. Cephalosporin PMB-ester 3 was first reacted 
with sodium iodide in acetone to substitute the chloride for iodide under Finkelstein conditions. 
The choice of acetone allowed dissolution of the soluble NaI while causing the by-product 
NaCl to precipitate from the reaction, driving the chloride to iodide substitution to completion. 
Solid 2) was then added to the reaction in one shot. The low solubility of DEA-NONOate 2 in 
acetone served to reduce the reagent’s basicity, limiting deprotonation of the acidic sulphide 
α-protons and resulting double bond migration to form the 2 isomer.  Only one of the four 
reactions showed any formation of the isomer (Reaction 4, 5-10% by 1H NMR analysis of the 
crude reaction product). Results from the reactions performed are summarised in Table 4 and 





Scheme 12. Mechanism of isomerisation to the 2 isomer via double bond migration triggered 
by abstraction of the acidic sulfide α-proton by basic nucleophiles. 
 
Table 4. Summary of reactions performed to produce 4. 
Reaction Starting mass of 3 (g) Yield 4 (mg) Yield (%) 2 isomer (%) 
1 0.5 130 22 0 
2 0.5 126 20 0 
3 1 278 23 0 
4 1 284 24 5-10 
 
 The purified (silica gel column chromatography) samples of 4 were analysed by 1H and 
13C NMR spectroscopy and their spectra compared to those published previously by the Kelso 





Figure 28. Top: 1H NMR spectrum of 4 published by the Kelso group.80 Bottom:  1H NMR 
(500 MHz, CDCl3) spectrum of 4 synthesised in this study. 
 
 The 1H NMR signals observed for the material prepared in this study perfectly matched 







Figure 29. Top: 13C NMR spectrum of 4 published by the Kelso group.80 Bottom: 13C NMR 
(125 MHz, DMSO-d6) spectrum of 4 synthesised in this study. 
 
 The 13C NMR spectrum showed the correct number of signals and similar chemical 
shifts to the published data. However, the spectrum was recorded in DMSO-d6 as opposed to 
CDCl3, causing the chemical shifts to move slightly. Thus, the 
1H NMR and 13C NMR spectra 
confirmed that compound 4 synthesised in this study was spectroscopically identical to that 




4.3 Deprotection of 4 to give DEA-C3D 1 
 I acknowledge Dr Ardeshir Rineh for assistance in the deprotection reaction. The final 
step in the synthesis involved removal of the p-methoxybenzyl (PMB) ester from 4 to give the 
free carboxylic acid. Deprotection was achieved by stirring 4 for 1-1.5 hours with neat 
trifluoroacetic acid (TFA) in molten phenol at 45 oC under argon. Purification of 1 was 
achieved using preparative reverse phase HPLC or reverse phase silica gel column 
chromatography (H2O, CH3CN mixtures), with the final product obtained after freeze-drying. 
A mechanism for the ester deprotection reaction is proposed in Scheme 13. 
 
 
Scheme 13. Mechanism of PMB-ester deprotection using TFA in phenol to produce the target 




 This mild TFA/phenol PMB-deprotection method was originally reported by Torii et 
al.113 and was adapted by the Kelso group for use with PMB-protected C3Ds.109 The molten 
phenol functions as the solvent for the reaction and also serves to rapidly scavenge the highly 
reactive quinone methide cation formed during loss of the PMB group.  The deprotection 
reaction was monitored using reverse phase TLC, where loss of the starting material spot and 
appearance of a new product spot were clearly observable. Once the reaction was completed, 
ether was added, and the reaction flask was placed on ice.  Unexpectedly, no precipitate of the 
crude 1 formed at this stage. Initially, it was thought that the volume of ether added was too 
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high, preventing precipitation. Further concentration under reduced pressure at room 
temperature did not trigger precipitation. Changing the solvent to petroleum spirit successfully 
precipitated 1 and it was isolated using a centrifugation. The crude was loaded with a small 
amount of CH2Cl2 onto a reverse-phase silica gel column and eluted using increasing 
concentrations of acetonitrile in water. Fractions containing the pure 1 by reverse phase TLC 
analysis were pooled and freeze-dried overnight to give a fluffy white powder. A summary of 
the deprotection reactions performed is shown in Table 5. 
 
Table 5: Summary of deprotection reactions to give 1. 
Reaction Starting amount of 4 (mg) Mass of 1 (mg) Yield (%) 
1 100 10 13 
2 60 23 48 
 
 The first attempt at the reaction gave only 10 mg of 1 from 100 mg of starting ester 4 
(13%) after reverse-phase column chromatography. The second attempt yielded 23 mg of 1 
from 60 mg of 4 (48%). The increased yield was attributed to improved techniques after having 
performed the reaction once already. The Kelso group reported recovery of 160 mg of 1 (81%) 
from 250 mg of 4 using their original procedure (neat TFA at room temperature).78 The lower 
yield obtained in this study was appeared to be caused by degradation of 4 reverse-phase 
column chromatography.  Nevertheless, sufficient quantities of pure, freeze-dried 1 were 
produced for this study.  
 The purified (silica gel column chromatography) samples of 1 were analysed by 1H and 
13C NMR spectroscopy and their spectra compared to those published previously by the Kelso 





Figure 30. Top: 1H NMR spectrum of 1 published by the Kelso group.80 Bottom:  1H NMR 
(500 MHz, CD3OD) spectrum of 1 synthesised in this study. 
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The 1H NMR signals observed for the material prepared in this study closely matched  
the chemical shifts and multiplicity patterns in the published data with minor impurity except 
the solvent resident peak (3.31, CD3OD) was more intense for this study than the published 
data. 
 
Figure 31. Top: 13C NMR spectrum of 1 published by the Kelso group.80 Bottom: 13C NMR 
with Proton Decoupling (125 MHz, DMSO-d6) spectrum of 1 synthesised in this study. 
 
The 13C NMR with proton decoupling spectrum contained the signals and similar 
chemical shifts to the published data. However, the spectrum was recorded in DMSO-d6 as 
opposed to CD3OD, causing the chemical shifts to move slightly. There were also addition 
signal peaks in the 13C NMR with proton decoupling spectrum which may be caused by 
degradation of 1 or impurities in the DMSO-d6. Attempts to isolate and characteristic these 
peaks from the 13C NMR with proton decoupling spectrum were unsuccessful as the 1H NMR 
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spectrum shows a complete match to the published data, concluding that the sample was pure 
when submitted to the NMR analysis. 
 
4.4 Nitric oxide release studies  
 I acknowledge Dr Ardeshir Rineh for training and assistance with the Apollo Free 
Radical Analyser used for NO release studies. At this stage of the project, the pure C3D 1 (4.3), 
TEM-1 β-lactamase (2.15) and TEM-1 β-lactamase-sulfo-SMCC-Fab' 528 conjugate (3.4) 
were in-hand and ready for proof-of-concept NO release studies.  The objective of these studies 
was to compare NO production from 1 following exposure to the two β-lactamase and establish 
whether addition of the SMCC-linker and Fab' 528 protein affects the activity. The 
experimental setup involved connecting a NO-selective probe to the free radical analyser.  The 
sensitive probe was placed in the middle of a two-neck round-bottom flask containing MilliQ 
water and the flask was sealed. The range of the sensor was set to 10 nA and the probe selector 
set to NO.  The setup was stabilized by stirring overnight or until a stable baseline signal was 
obtained.  
 After equilibrating the probe, the instrument was calibrated to enable accurate 
determination of NO concentrations in the test solutions. This was achieved using standard 
solutions containing known concentrations of nitric oxide in water. Saturated nitric oxide 
solution (1.91 mM), generated by continuously bubbling the gas into MilliQ water, was diluted 
10-fold to 191 µM.  Test solutions of different concentration were prepared by adding 
increasing amounts of 191 µM stock solution and added to the flask containing the probe and 
the change in current was recorded.  The NO calibration curve was generated by transforming 







Figure 32.  Top: Measurement of NO levels in standard aqueous solutions to generate a 
standard curve.  Aliquots of 100 µL, 200 µL, 400 µL, 800 µL, 1600 µL of a standard NO 
solution (191 µM) were added to 20 mL of water and the NO signal (current pA) was recorded. 
The corresponding NO concentration is shown on the right axis. (B) Standard curve for NO 
concentrations in water.  
 After calibrating the probe, the water in the flask was replaced with 20 mL of fresh 
phosphate-buffered saline (PBS).  The calibrated NO probe was left in the stirring PBS solution 
until the signal stabilised.  While the probe was stirring DEA-C3D 1, TEM-1 β-lactamase and 















































































allowed to warm to room temperature. TEM-1 β-lactamase and the conjugate were diluted from 
3600 U and 2500 U, respectively, to 30 U.  Once the signal had stabilised, 2 mg of DEA-C3D 
1 was added to the stirring PBS and the signal was recorded for 10 minutes.  100 µL of 30 U 
TEM-1 β-lactamase was then injected into the solution and NO was rapidly detected. When 
the signal reached a plateau, a 200 µL aliquot was added.  Additional aliquots with doubling 
volumes were subsequently added when the signal from the previous aliquot had reached a 
plateau. The process was repeated until the NO signal saturated, usually within 1-1.5 hours 
after addition of 3 aliquots. The same method was repeated on the TEM-1 β-lactamase-sulfo-
SMCC-Fab' 528 conjugate. The NO signal reaches the maximum presumably when all the 
DEA-C3D substrate has been ring-opened by the β-lactamase and all of the DEA-NONOate 







































Figure 33. NO concentrations in PBS solutions containing DEA-C3D 1 (100 mM) following 
addition of Top: TEM-1 β-lactamase. Arrows indicate addition of the following to reaction 
vials: (a) 100 µL of 30 U/mL TEM-1 β-lactamase, (b) 200 µL, (c) 400 µL. Bottom:  TEM-1 β-
lactamase-sulfo-SMCC-Fab′528 conjugate. Arrows indicate addition of the following to 
reaction vials: (d) 100 µL of 30 U/mL TEM-1 β-lactamase-sulfo-SMCC-Fab′528, (e) 200 µL, 
(f) 400 µL. 
 
The TEM-1 β-lactamase and the β-lactamase-sulfo-SMCC-Fab′ 528 conjugate both 
clearly catalysed the hydrolysis of 1, leading to release of NO into the solution. The NO 
concentration steadily increased over time until reaching a plateau. The first NO plateau for the 
TEM-1 β-lactamase occurred after 40 minutes and for the β-lactamase-sulfo-SMCC-Fab′ 528 
conjugate it occurred after 80 minutes. Since the same amount of enzyme activity units were 
added to each reaction (30 U/mL according to nitrocefin assay, 2.13) the lower rate of NO 
production by the conjugate suggests its β-lactamase component is less active towards the C3D 
substrate 1 than the unconjugated TEM-1 parent enzyme. Second injections of the enzymes 


































injection produced very small responses, suggesting that all the DEA-C3D 1 had been 
consumed. 
 It is believed that the further releases of NO into the solution from the initial reaction 
is caused by NO reaching a steady state. This means that the rate of NO produced is equal to 
the rate of NO decomposition. Additional β-lactamase injection increases the rate of NO 
produced until the system reaches steady state again. Another theory is that the acylated β-
lactamase is being hydrolysed only slowly, thus the rate of NO production is slowed. A third 
possibility is that the β-lactamase is being covalently modified by the NO being produced, 
leading to inactivation. Further studies are required to confirm these theories. 
The initial rates of reaction were obtained from the gradients of the curves after addition 
of the respective enzymes. The amount of DEA-C3D 1 consumed during the experiments was 
determined for each enzyme by dividing the area under the curve by two, since each mole of 1 






Figure 34. NO release from 1 by TEM-1 β-lactamase. Gradients and areas under the curve 
after each injection of the enzyme are shown in the table. 
 
 
Figure 35. NO release from 1 by TEM-1 β-lactamase-SMCC-Fab′ 528 conjugate. Gradients 
and areas under the curve after each injection of the enzyme are shown in the table. 
 
 From the plots and tables, it was clear that the TEM-1 β-lactamase shows a higher rate 
of reaction with DEA-C3D 1 than the β-lactamase-sulfo-SMCC-Fab′ 528 conjugate. The rates 
of reactions were obtained by creating tangent lines at the Km of each addition. The Km was 
determined by halving the NO concentration at the plateau, where the sample almost reached 
Vmax. The estimated Km chosen for the wild-type β-lactamase plot was extracted at 20 
minutes for the first aliquot, 45 minutes for the second aliquot and 65 minutes in the third.  
Similarly, the estimated Km for the β-lactamase-sulfo-SMCC-Fab′ 528 conjugate was taken at 
40 minutes for the first aliquot, 100 minutes for the second and 145 minutes for the third. The 
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gradient of the tangent at the estimated Km was used as the rate of reaction, as shown in the 
tables in Figures 34 and 35. The areas under the three aliquot curves were also calculated for 
the enzymes. This represented the total NO released during that reaction period. It is noted, 
however, that NO is lost from the solutions with time due to its reactivity, meaning that the 
extracted values underestimate the actual amount of NO released. It was seen that the TEM-1 
β-lactamase produced almost three times the amount of NO after the first and second aliquots, 
compared to the β-lactamase-sulfo-SMCC-Fab′ 528 conjugate. The β-lactamase-sulfo-SMCC-
Fab′528 conjugate also took twice as long to reach saturation. It is postulated that the reduced 
activity arises because of   the non-specific bioconjugation method that was used to create the 
























 The aims of this project were: (1) to clone, express and purify a TEM-1 β-lactamase, 
(2) conjugate it to a model antibody fragment using a bifunctional linker, (3) synthesise the 
cephalosporin-3'-diazeniumdiolate DEA-C3D 1 and (4) use 1 as substrate and testing for NO 
release by the TEM-1 β-lactamase and β-lactamase-sulfo-SMCC-Fab' 528 conjugate. The 
TEM-1 β-lactamase was expressed in good yield and conjugated to the thiol-bearing antibody 
fragment Fab' 528 using a sulfo-SMCC crosslinker. DEA-C3D 1 was synthesised, isolated and 
characterised using the previously reported methods. NO release experiments showed that the 
TEM-1 β-lactamase produced more NO from DEA-C3D 1 and at a faster rate than the TEM-1 
β-lactamase-SMCC-Fab' 528 conjugate. Overall, the study has demonstrated for the first time 
that it is possible to produce a β-lactamase-Fab' 528 conjugate that triggers NO release from 
C3Ds opening the way for further studies aimed at achieving tissue selective NO delivery via 





Scheme 14. Summary of aims completed in the project. (1) Cloning, expression and 
purification of a TEM-1 β-lactamase (2) conjugation of the TEM-1 β-lactamase to the antibody 
fragment Fab' 528 to produce a TEM-1 β-lactamase-SMCC-Fab' 528 conjugate (3) synthesis 
of DEA-C3D 1 (4) measurement and comparison of the catalytic activity of the two β-
lactamases in generating NO from 1. 
 
5.2 Future directions 
 While the first molecular proof-of-concept has been achieved in the project, a wide 
variety of improvements could now be pursued. One possibility would be to explore more site-
specific protein bioconjugation methods using different mutants of the TEM-1 β-lactamase, 
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aiming to improve enzyme activity. Once optimal conjugation chemistry has been identified, 
functional proteins of interest could then be attached, including a monoclonal antibody but also 
fluorescent proteins, peptides, polymers or single chain antibody fragments. Alternative C3Ds 
with different β-lactamase susceptibilities could also be explored, especially if the approached 
moved closer towards clinical application where in vivo drug properties of the C3D would be 
an important consideration Ultimately, our long-term goal is to explore an ADEPT strategy 
employing the plaque-targeting antiLIBS scFv antibody with a C3D to create a targeted NO 
treatment for emergency interventions in heart attacks caused by atherosclerotic plaques (1.12). 
 
5.2.1 Site-specific bioconjugation 
 In this project, the crosslinker chosen for protein bioconjugation was sulfo-SMCC, 
which gave rise to non-site-specific TEM-1 β-lactamase functionalisation through lysine side 
chain amines and (and/or N-terminus). Two site-specific bioconjugation methods routinely 
used in the Williams Laboratory at CSIRO making use of click chemistry114 and Sortase-
mediated reactions115 could be investigated. 
 
5.2.1.1 Click chemistry approach 
 Bioconjugation using Click chemistry has been widely published.116 A mild (i.e. 
protein-friendly), bio-orthogonal copper-free click chemistry approach could potentially be 
used to conjugate proteins of interest (e.g. antiLIBS scFv antibody) to TEM-1 β-lactamase 
(Scheme 15). In this approach, the β-lactamase could be reacted with an NHS or 
tetrafluorophenol (TFP) ester PEGx azide. These are commercially available 
heterobifunctional crosslinking reagents that come in a range of PEG chain lengths. The 
antiLIBS scFv antibody engineered with a C-terminal cysteine residue from Karlheinz Peter 
laboratory, could then be reacted with a maleimide-PEGx dibenzocyclooctyne (DBCO) 
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linker. Conjugation of the azide-modified β-lactamase and the DBCO-modified antiLIBS scFv 
antibody would proceed via the well documented, strain-promoted 1, 2-dipolar cycloaddition 
of the DBCO group and the organic azide.117 Different length PEG linkers could be 
investigated, the choice of which would be guided by the measured activity of both the β-
lactamase and antiLIBS scFv antibody portions. The opposite combination of cross-linkers 
could also be explored, where the DBCO group is installed on the TEM-1 β-lactamase and 
the azide on the antiLIBS scFv antibody. Although the reaction to lysine amines on the β-
lactamase in the initial step, by reaction with the TFP ester, can be heterogeneous (multiple 
Lysine amine residues on the BLA protein), the azide group that has been installed is a stable 
reagent and is selective to reaction with alkyne groups such as the DBCO group. This method 
is more likely to lead  to a homogenous conjugate and  purification is expected to be easier.  
 
 
Scheme 15. Copper-free Click chemistry bioconjugation approach to a TEM-1 β-lactamase-
antiLIBS scFv antibody conjugate 
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5.2.1.2 Sortase-mediated approach 
Sortase-mediated bioconjugation uses the enzyme Sortase A to covalently link two 
molecules, usually proteins.118 The Sortase A enzyme recognises and selectively binds to a 
penta-peptide recognition sequence, LPETG, which can be added to almost any protein. Sortase 
A has a conserved cysteine residue in its active site that reacts with the carbonyl carbon of the 
threonine residue (T) in the pentapeptide motif to form a thioester intermediate. The thioester 
is then attacked by a nucleophile, which in nature is triglycine with the N-terminal primary 
amine forming an amide bond at the threonine carbonyl. The C-terminal glycine residue of the 
LPETG motif is cleaved off in the process and the Sortase A active site regenerated for further 
reactions. A β–lactamase engineered to contain a GGGG sequence (Construct 3, 2.2) could 
potentially be used in a Sortase A-mediated bioconjugation strategy. A scFv has been 
engineered  to contain the LPETG Sortase-recognition sequence in our collaborator’s 
laboratory (Prof Karlheinz Peter).100 This LPETG-modified antibody fragment could be 
submitted to Sortase-mediated bioconjugation with a GGGG-tagged TEM-1 β-lactamase to 
produce a scFv-TEM-1 β-lactamase conjugate. (Figure 36). This method would likely be 
cleaner and more site-specific than the SMCC, thiol-maleimide and Click chemistry methods. 
Extra amino acids could be added to either the scFv or the TEM-1 β-lactamase in front of the 




Figure 36. Sortase A-mediated bioconjugation approach using a LPETG-modified scFv and 




5.2.2 β-lactamase mutants 
 In this project, a wild-type TEM-1 β-lactamase was chosen as the first model β-
lactamase for exploring antibody conjugation and NO release with C3Ds. However, there are 
several mutant variants of TEM-1 β-lactamase that are known, which could potentially be used 
to refine enzymatic efficiency and/or alter protein stability.119-121 One useful mutant contains a 
single point mutation (E166N) that lowers β-lactamase activity by 1,000,000-fold.104 This 
‘inactive’ mutant  could serve as an appropriate negative control in NO release experiments 
moving forward, both in vitro and in vivo. Another mutant, E166Y, has been shown to have 
100-times higher cephalosporinase activity than the wild-type enzyme.122 This ‘super-
lactamase’ mutant could be used to prepare higher activity conjugates. Studies involving 
conjugation of proteins of interest to β-lactamases from other families, such as the extended 
spectrum β-lactamases (ESBL) or the SHV strain, could also be explored.123  
 
5.2.3 Modifying the C3D structure 
 In C3Ds, the β-lactam and diazeniumdiolate portions are crucial functional 
components. However, the group attached at the C7 position and the diazeniumdiolate structure 
can be modified to increase susceptibility to β-lactamases and modulate drug properties.109 In 
this work, a phenacyl group was attached at C7 in DEA-C3D 1 and the diazeniumdiolate was 
derived from diethylamine. The Kelso group have synthesised and studied several C3D 
analogues carrying different C7 groups diazeniumdiolates. Examples like 5-8 (Figure 37) could 





Figure 37. Examples of C3Ds from the Kelso group carrying variations in the C7 side chain 
and diazeniumdiolate. 
 
5.2.4 Long term goal: An emergency intervention during heart attacks caused by 
atherosclerotic plaques 
 As discussed earlier, a possible medical application of a NO-targeting ADEPT strategy 
could be in the treatment of heart attacks caused by atherosclerotic plaques, where the plaque 
occludes a coronary vessel leading to myocardial ischemia. An emergency ADEPT 
intervention could perhaps be given by paramedics to patients suffering this type of heart attack 
that aims to achieve localised NO therapy and vasodilation directly at the site of the artery 
occlusion. The vasodilation could increase blood flow around the occlusion and reduce 
myocardial ischemia, keep the patient alive long enough to undergo emergency surgery to 
remove the blockage. The ADEPT therapy could comprise a β-lactamase conjugated to the 
plaque-targeting antiLIBS scFv antibody (Prof Karlheinz Peter) and a C3D. When administered 
to the patient, the antiLIBS scFv-β-lactamase conjugate would localise β-lactamase activity to 
the immediate vicinity of the artery blockage. After some minutes, administration of the C3D 
would lead to NO delivery exactly at the required site, triggering vasodilation and increased 
blood flow (Figure 38). In addition to this potential ADEPT application, one can imagine 
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targeting NO to just about any tissue through tissue-specific antigen-antibody interactions, 
where a relevant antibody is linked to a β-lactamase and used with a C3D.  
 
 
Figure 38. ADEPT approach for targeting vasodilating NO to occluded artery sites during 




































The TEM-1 β-lactamase DNA and plasmids were designed by Dr. Stewart Nuttall and 
expressed by Genscript. DH5-α cells were provided by CSIRO. TB Broth was made by 
dissolving yeast extract (2.4% w/v), tryptone (2.0% w/v) and glycerol (0.4% w/v) in sterile 
water and sterile phosphate buffer (10% v/v). PBS was formulated using Na2HPO4 (10 mM), 
NaCl (137 mM), KH2PO4 (1.8 mM) and KCl (2.7 mM) in MilliQ water. 2 x YT medium was 
made from 1.6% (w/v) tryptone, 1.0% (w/v) yeast extract and 0.5% NaCl in sterile water. All 
buffers and media used for cell culturing were filtered through a 0.22 µm sterile filter before 
use. Miniprep kits were purchased from Qiagen and the NucleoSpin Gel and PCR Clean-Up 
kit was obtained from Macherey Nagel. All restriction enzymes, primers and DNA ladders 
were from New England BioLabs. SYBR Safe DNA Gel Stain was supplied by Thermo Fisher. 
DNA gels were run on BioRad electrophoresis instruments and analysed using a LICOY 
Odyssey imaging system.  
Protein gels were run using 4-12% Bis Tris Pre-Cast gel 10 or 15 wells from NuPAGE, 
Life Technologies on an XCell SureLock Mini cell. Protein concentrations were measured 
using a Nanodrop spectrophotometer at 280 nm. MALDI-TOF mass spectra of proteins were 
acquired by Dr. Tom Nebl at Parkville, CSIRO. Nitrocefin was purchased from Biovision. 
SMCC was purchased from Thermo Fisher. Protein samples were concentrated using 
Amicon® Ultra-4 spin or Amicon® Ultra-15 spin filters with a 30 kDa molecular weight cut-
off. Protein purification chromatography was monitored at 280 nm, 254 nm and 214 nm. 
All chemical reactions were performed under an argon atmosphere in oven-dried 
glassware with magnetic stirring. 7-Phenylacetamido-3-chloromethyl-3-cephem-4-carboxylic 
acid-p-methoxybenzyl ester (3 was purchased from AK Scientific. Phenol, sodium iodide, 
molecular sieves (3 Å and 4 Å) were purchased from Sigma-Aldrich. Molecular sieves were 
activated by drying overnight in a muffle furnace at 300 oC. Anhydrous ether was distilled from 
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sodium benzophenone ketyl under argon. Anhydrous methanol was heated at reflux over 4 Å 
molecular sieves for 4 hours and distilled onto 3 Å molecular sieves under argon.  Diethylamine 
was heated at reflux over CaH2 for 2 hours before distillation onto 4 Å molecular sieves under 
argon. Anhydrous acetone was obtained by heating analytical grade acetone over CaSO4 
(Drierite) granules for 1-2 hours under argon before distilling onto 4 Å molecular sieves. All 
other solvents were analytical reagent (AR) grade and used without further purification. NO(g) 
was purchased from Sigma Aldrich. Concentration under reduced pressure was performed by 
rotatory evaporation at 40 oC unless otherwise stated. The term petroleum spirit refers to 
hydrocarbon mixtures with a boiling range of 40-60 oC. 
Silica gel column chromatography was performed using SiliaFlash P60 230-400 mesh 
silica gel (Silicycle) with the indicated eluents. Reverse-phase silica gel column 
chromatography was performed using C18 (Carbon 17%) 60 Ǻ 40-63 µm silica gel. TLC 
analysis for reaction monitoring was performed using SiliaPlate TLC aluminium-backed 200 
µm plates (Silicycle). Compounds were visualised on TLC plates under UV light at 254 nm. 
Samples from reverse-phase silica gel column chromatography purifications were freeze-dried 
on a CHRIST Alpha 1-2 LD plus instrument at -53 oC and 0.15 mbar. 1H NMR and 13C NMR 
were recorded on either Varian Unity-300 MHz or Varian-Inova-500 MHz spectrometers in 
the indicated deuterated solvents (DMSO-d6 or CD3OD). The spectra were referenced to the 
chemical shifts of the residual undeuterated solvent signals. Melting points were determined 
using a Buchi Melting Point M-560 apparatus and are uncorrected. Optical rotations were 




6.2 Molecular Biology 
6.2.1 Digestion of TEM-1 β-lactamase wild type inserts 
Lyophilised TEM-1 β-lactamase DNA was resuspended in distilled water (100 µL) and 
transformed into DH5-α cells. The DH5-α cells were cultured in TB Broth (5 mL) with 
ampicillin (100 µg/mL) overnight. An aliquot of the cells was mixed with 50% glycerol and 
stored as a backup in -80 oC. The rest of cells were spun down at 4,000 rpm for 10 min at 4 oC 
and the supernatant discarded. Mini preps were performed according to the manufacturer's 
instructions on the pellet to extract the high-quality DNA. 
The insert was obtained by double digesting the high-quality DNA (160 ng/uL) vector 
with the restriction enzymes BamH1-HF (20 U/ul) and NheI-HF (20 U/ul) in (10x) CutSmart 
Buffer for 1.5 hours at 37 oC. A 1% (w/v) agarose gel with 1:10,000 SYBR Safe dye was 
prepared in Tris-acetate-EDTA (TAE) buffer (Tris base (2 M), glacial acetic acid (1 M), 0.5 M 
EDTA pH 8.0). The digested vector was loaded onto the 1% agarose gel and run for 30 minutes 
at 150 V with 1 kB and 500 bp DNA ladder present. The insert band was excised under UV 
with a gel knife and the DNA extracted from the gel using the NucleoSpin Gel and PCR Clean-
Up kit according to the manufacturer’s instructions. The insert DNA (14.3 ng/µL) was stored 
in the -20 oC freezer. 
 
6.2.2 Digestion of the pET43.1α vector 
The pET43.1 vector (556 ng/µL) was double digested with the restriction enzymes 
BamH1-HF (20 U/ul) and NheI-HF (20 U/ul) in (10x) CutSmart Buffer for 1.5 hours at 37 oC. 
A 1% (w/v) agarose gel with 1:10,000 SYBR Safe dye was prepared in Tris-acetate-EDTA 
(TAE) buffer (Tris base (2M), glacial acetic acid (1M), 0.5M EDTA pH 8.0). The digested 
plasmid was loaded on to the 1% agarose gel and run for 30 minutes at 150 V with 1 kB and 
500 bp DNA ladders. The vector band was excised under UV light and extracted from the gel 
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using the NucleoSpin Gel and PCR Clean-Up following the manufacturer’s protocol. The 
pET43.1α vector (6 ng/µL) was stored in the -20 oC freezer. 
 
6.2.3 Ligating TEM-1 β-lactamase inserts into open pET43.1a vectors 
Digested insert DNA, digested vector DNA, T4 ligase buffer (10x), T4 DNA ligase and 
MilliQ water were added into a microeppendorf at room temperature for 15 minutes, as 
indicated in Table 6. A negative control containing no insert was included. 
 










6.2.4 Transformation into competent DH5-α E. coli cells 
Ligated vector (10 µL) was gently mixed with 50 µL of competent DH5-α E. coli cells 
on ice for 10 minutes. The cells were subjected to heat shock at 42 oC for 45 seconds and 
returned to ice for 2 minutes. The transformed cells were supplemented with 100 µL 2x YT 
medium with ampillicin (100 µg/mL).  The transformed sample and the control were spread 
evenly on YT-Amp plates. The plates were incubated overnight at 37 oC with the agar side up. 
 
Reagent Sample volume (µL) Control volume (µL) 
Insert DNA (14.3 ng/µL) 4.2 - 
Vector DNA (6 ng/µL) 2 2 
T4 DNA Ligase (20 KU) 1 1 
T4 Ligase buffer (10x) 1 1 
MilliQ water 1.8 6 
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6.2.5 Agarose gel DNA electrophoresis 
  A 1% (w/v) agarose gel was prepared in TAE buffer (Tris base (2 M), glacial acetic 
acid (1 M), 0.5M EDTA pH 8.0) with 1:10,000 SYBR Safe dye. DNA samples were mixed 
with 6x DNA loading dye (Thermo Fisher) and loaded onto the agarose gel well comb. DNA 
ladders (10 µL) 1 Kbp and 500 bp DNA were added to other lanes in the gel. The gel was run 
in 1x TAE buffer at 110 V for 30 minutes and visualised under UV light at 600 nm. The gel 
was placed on a UV box and the DNA of interest was excised using a gel knife. The DNA was 
recovered using the NucleoSpin Gel and PCR Clean-Up kit. 
 
6.2.6 Colony screening PCR 
Using a sterile inoculation loop, 6 random colonies from the positive transformation 
plate and one control colony were selected, dipped into separate empty PCR tubes and streaked 
onto new patch plates (YT-Amp), which were grown overnight at 37 oC. A Master Mix was 
created containing 5 µL of 2xGoTaq® Green (GTG, Promega), 0.5 µL of T7 Forward primers 
(10 µM), 0.5 µL of Coli Down (10 µM) and 4 µL of distilled water per colony on ice. 10 µL 
of Master Mix was added to each empty PCR tube on ice. PCR reactions were performed on 
the colonies’ sample using the following PCR parameters (Table 3). 1% (w/v) agarose gel with 
1:10,000 SYBR Safe dye in Tris-acetate-EDTA (TAE) buffer was used to analyse the positive 
clones as described in section 6.2.5. Gels were analysed on the LICOY Odyssey imaging 
system. 
 
6.2.7 Sequencing PCR 
A colony sample of the positive clones from the patch plates was inoculated in fresh 5 
mL of sterile YT-Amp media and incubated overnight at 37 oC.  An aliquot was taken from the 
overnight colonies and mixed with 50% glycerol (v/v) to store at -80 oC as a backup sample. 
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The overnight samples were spun down at 4,000 rpm for 10 min at 4 oC and the supernatant 
discarded. Minipreps were performed on the pellets, according to the manufacturer's 
instructions, to extract the DNA from the cells. The DNA samples were sent to Micromon 
(Monash University, Victoria, Australia) for Sanger DNA sequencing. DNA sequencing 
chromatograms were analysed using Chromas. 
 
6.3 Expression and purification of recombinant TEM-1 β-lactamase  
6.3.1 Analytical protein expression studies 
 Positive clone DNA (0.5 µL, 82 ng/µL) was added to 50 µL BL21-DE3 E. coli cells. 
The cells were incubated for 10 minutes on ice, treated for 45 seconds with heat shock at 42 oC 
and then placed on ice for another 2 minutes.  2 x YT media (100 µL) supplemented with Amp 
(100 µg/mL) was then mixed with the sample on ice. The samples were grown on separate YT-
Amp plates overnight at 37 oC. A single positive colony from the overnight plates was picked 
and inoculated into 5 mL 2xYT media containing 100 µg/mL Amp overnight at 37 oC with 
shaking at 150 rpm. The overnight cultures were used to inoculate another 5 mL fresh 2xYT-
Amp media with a starting OD600nm of 0.1. The OD600nm was measured on a spectrophotometer 
(Eppendorf) and cultures were grown in a shake incubator (Raytek) at 37 oC with shaking 180 
rpm until the culture OD600nm reached 0.7-0.8.  TEM-1 β-lactamase expression was induced by 
addition of 0.5 mM IPTG into the culture. The induced culture was incubated at 16 oC overnight 
with shaking at 180 rpm in a HT Ecotron shaking incubator with integral cooling (Infors). The 
cells were harvested by centrifugation at 4,000 rpm for 10 min at 4 oC using a JA 25.50 
centrifuge (Beckman Coulter). The bacterial cell pellets were lysed using 500 µL Bugbuster 
Protein Extraction Reagent (Merck). Both the soluble fraction and the insoluble fraction 




6.3.2 Protein SDS-Page Gels and Western Blotting 
Proteins were analysed by SDS–PAGE under non-reducing conditions on a 4–12% 
Bis–Tris NuPAGE gel using MES electrophoresis buffer (50 mM MES, 50 mM TRIS, 0.1 % 
SDS, 1 mM EDTA pH 7.3). For reducing conditions, DTT (5 mM) was added to the 4x LDS 
sample buffer. The samples were incubated with 4x LDS sample buffer and heated to 70 oC for 
5 minutes prior to loading into separate wells of the gels. 5 µl of See Blue 2 pre-stained 
molecular weight ladder was added in lane 1 to estimate the molecular weight of proteins. Gels 
were placed in a Surelock MiniCell filled with fresh MES running buffer and run at 150 V for 
40 minutes. Gels were then stained with Coomassie Brilliant Blue to detect the denatured 
proteins (0.1 % w/v Coomassie Brilliant Blue R250 dissolved in 40 % v/v ethanol/10 % v/v 
glacial acetic acid) for 30 mins at room temperature on a rocking platform followed by multiple 
rounds of de-staining with 10 % v/v ethanol/7.5 % v/v glacial acetic acid at room temperature 
(on a rocking platform). 
Western blots were performed by transferring the replicate gel onto a nitrocellulose 
membrane (Protran 0.45 µm nitrocellulose membrane, Perkin Elmer) using transfer buffer (25 
mM Bicine, 25 mM Bis-Tris, 1 mM EDTA pH 7.2 and 10 % v/v methanol) at 25 V for 90 mins. 
Transferred membranes were blocked in PBS containing 5% (w/v) skim milk powder and 0.1% 
Tween-20 (v/v) (Blotto) for 30 minutes, and incubated with an anti-His tagged monoclonal 
antibody horseradish peroxidase conjugate (Sigma) diluted 1:4000 with Blotto to detect His 
tagged proteins. The membranes were washed several times with PBS containing 0.1% Tween-
20 (v/v) before being developed using a chemiluminescent substrate (Super-signal West Pico 
PLUS chemiluminescent substrate, (ThermoScientific) and imaged using an Amersham Imager 




6.3.3 Large scale TEM-1 β-lactamase expression 
   The positive colony picked from the overnight small-scale expression plate was 
inoculated into fresh 2 x YT media (12.5 mL) supplemented with Amp (100 µg/mL). The 
culture was grown overnight at 37 oC with shaking at 150 rpm.  The overnight culture was used 
to inoculate 1 L TB media containing 10% potassium chloride. The media was decanted into 
two 500 mL sample volumes in 2 x 2 L Tunair shake flasks and incubated at 37 oC with shaking 
at 180 rpm. Cells were grown until the OD600nm reached 0.7-0.8. Control samples were taken 
for SDS-gel and Western Blotting. IPTG (0.5 mM) was used to induce the cultures. The 
induced cultures were moved into a 16 oC incubator and shaken at 180 rpm overnight. The cells 
were spun down at 6000 g at 4 oC for 10 minutes on a F500 rotor, the supernatant discarded, 
and the pellets frozen at -80 oC. 
 
6.3.4 Extraction and purification of TEM-1 β-lactamase  
6.3.4.1 Cell lysis 
Cell pellets from section 6.3.3 were resuspended in lysis buffer (PBS with 0.02 % NaN3, 
150 mM NaCl, 2 mM MgCl2 , 10 mM imidazole, 0.5 mg/mL lysozyme, 5 ul benzonase, 1 mM 
PMSF and 3 tablets of protease inhibitor pellets) in a proportion of 10 mL buffer per gram of 
cells. The lysis buffer was stirred for 10-20 minutes at 4 oC or until the mixture was 
homogeneous. Cells were then placed in the chilled EmulsiFlex C5 high pressure homogeniser 
(Avestin) three times at 15, 000 psi before the flowthrough was poured into 50 mL centrifuge 
tubes and spun down in a JA25.50 rotor at 18 000 g for 20 minutes at 4 oC.  The supernatant 
was collected and concentrated using Amicon®-15 10,000 MW cut off spin filters. The pellet, 
supernatant and uninduced control samples were analysed by SDS-PAGE gel electrophoresis 
under non-reducing conditions (6.3.2). For sonication as an alternative to the cell crusher, the 
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solution was sonicated on ice using a program with the amplitude set to 60 Hz and the sample 
subjected to a 30 second pulse followed by a 60 second rest for 10 cycles. 
 
6.3.4.2 Immobilized metal affinity chromatography 
Concentrated supernatant was mixed with imidazole (10 mM) before loading onto a 5 
mL HiTrap column (GE Healthcare Life Sciences) connected to a Profinia™ Affinity 
Chromatography Protein Purification System (BioRad). TEM-1 β-lactamase were eluted using 
20 column volume (cV) binding buffer (PBS with 0.02% NaN3, 150 mM NaCl, 10 mM 
imidazole), followed by 20 cV wash buffer (PBS with 0.02% NaN3, 150 mM NaCl, 20 mM 
imidazole) and then 5 cV elution buffer (PBS with 0.02% NaN3, 150 mM NaCl, 250 mM 
imidazole). The eluted fractions were concentrated, and SDS-PAGE gel analysis was 
performed on each step of the column purification under non-reducing conditions. 
 
6.3.4.3 Protein purification 
Elution fractions containing protein samples from IMAC were injected onto a 
HiLoad® 26/600 Superdex® 200 column connected to an AKTA Pure system and eluted using 
PBS. The column was run at 2 mg/min for 1.5 cV. A standard molecular weight ladder run on 
the same column was used to estimate the molecular mass of eluting peaks (Table 7). Peak 
fractions were pooled and concentrated. Samples were run on SDS-PAGE gels and Western 
Blots under non-reducing and reducing conditions (6.3.2) and mass spectrometry was 
performed. 
 
Table 7. Standard molecular weight ladder for protein purification. 
Component Molecular Weight (Da) Sigma-Aldrich 
Thyroglobulin (bovine) 670,000 T9145-1VL 35 mg 
γ-globulin (bovine) 158,000 G5009-1g 
Ovalbumin (chicken) 44,000 A5503-1g 
Myoglobin (horse) 17,000 M1882-250 mg 
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Vitamin B12 1,350 V2876-100 mg 
 
6.3.5 TEM-1 β-lactamase stability and function studies 
Protein samples at 1 mg/mL and PBS were examined for buffer stability and pH 
stability by the CSIRO Collaborative Crystallisation Centre labs (Parkville, Melbourne). 
 
6.3.6 Enzyme activity 
Enzyme activity of the TEM-1 β-lactamase was measured by nitrocefin assay using the 
protocol supplied by BioVision. A standard curve was obtained to quantitate the activity 
(Appendix 3). 
 
6.3.7 His-TEV tag removal  
 TEM-1 His-TEV-β-lactamase (3.46 mg/mL) were incubated with in-house His-TEV 
protease at a molar ratio of 1:15 with DTT (1 mM) for 12 hours in the refrigerator.  Imidazole 
(20 mM) was added and the cleaved TEM-1 β-lactamase was purified using IMAC on a 1 mL 
His tag column using the Profinia system. The column was washed using 5 cV of binding buffer 
(PBS with 0.02% NaN3, 150 mM NaCl, 20 mM imidazole), followed by 5 cV wash buffer 
(PBS with 0.02% NaN3, 150 mM NaCl, 20 mM imidazole) and ended with 5 cV elution buffer 
(PBS with 0.02% NaN3, 150 mM NaCl, 250 mM imidazole). The collected fractions were 
analysed using SDS-PAGE gel electrophoresis at 150 V for 40 minutes. A western blot using 
anti-His mouse antibody was performed to confirm removal of the His-tag. 
 
6.4 Bioconjugation chemistry 
6.4.1 Synthesis of TEM-1 β-lactamase-sulfo-SMCC-Fab′ 528 conjugate 
TEM-1 β-lactamase (50 µL, 0.016 µmol, 2 mg/mL) was reacted with sulfo-SMCC (3.2 
µl, 0.16 µmol, 22 mg/mL) in a final volume of 100 µL PBS for 1 hour at room temperature. 
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The reaction was desalted using a 5 mL HiTrap desalting column (GE) attached to an AKTA 
pure system using PBS as eluent at a flow rate of 5 mL/min. The peak containing the TEM-1 
β-lactamase-SMCC adduct was pooled and concentrated using Amicon® Ultra-4 spin filters.  
The protein concentration was measured using a Nanodrop spectrophotometer at 280 nm 
Dr. Judy Scoble from CSIRO generously provided the antibody fragment Fab' 528. Fab' 
528 (180 µL, 0.001 µmol, 0.56 mg/mL) was reduced using TCEP (20 µL, 0.1 µmol, 5 mM) for 
1 hour at 4 oC. The reaction was desalted using a 5 mL HiTrap desalting column attached to an 
AKTA pure system using PBS as eluent at a flow rate of 5 mL/min. Peaks containing the Fab′ 
528 were pooled and concentrated using Amicon® Ultra-4 spin filters and the protein 
concentration was measured using a Nanodrop spectrophotometer at 280 nm. 
TEM-1 β-lactamase-SMCC (0.5 mg/mL) and Fab′ 528 (0.5 mg/mL) were mixed at 
room temperature overnight. The sample was purified on a Superdex 200 increase 10/300 GL 
column (GE) attached to AKTA Pure using PBS as eluent at a flow rate of 1 mL/min. Samples 
containing the protein were pooled, concentrated and SDS-PAGE gels were performed under 
non-reducing and reducing conditions. Mass spectrometry analysis was also performed. 
 
6.5 Chemical synthesis 




Sodium methoxide solution was freshly prepared by dissolving sodium metal (2.5 g) 
into dry methanol (25 mL) and sonicating for 1 hour until clear.  Anhydrous diethylamine (7 
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g, 0.1 mol) was then added to the sodium methoxide solution followed by anhydrous diethyl 
ether, bringing the solution to a total volume of 300 mL.  The solution was decanted into a 
Parr-Knorr shaker attached to a NO cylinder and reacted for 3 days with shaking at 50-55 psi.  
After completion of the reaction, the solution was carefully depressurised and unsealed and 
vacuum filtered under a stream of dry nitrogen to obtain 2 as a white solid. The solid 2 was 
washed with copious dry diethyl ether, dried under high vacuum and stored under argon in a 
sealed dry flask wrapped in foil in the freezer (3.8 g, 25%). 
 






ester 3 (0.5 g, 1 mmol) was stirred with sodium iodide (0.154 g, 1 mmol) in dry acetone (8 mL) 
under argon in the dark at room temperature for 1 hour.  Freshly prepared sodium DEA-
NONOate 2 (0.160 g, 1 mmol) was added in one shot to the reaction mixture and the reaction 
stirred for another 1.5 hours under nitrogen while monitoring by TLC analysis (petroleum 
spirit: ethyl acetate, 2:1). Upon completion of the reaction, the solvent was removed under 
reduced pressure and the residue purified by gradient silica gel column chromatography (0-
50% ethyl acetate in petroleum spirit) to give 4 (126 mg, 20%) as an off-white solid. 
1H NMR: (500 MHz, CDCl3): δ 7.36-7.24 (m, 7H), 6.88 (d, 2H, J = 9 Hz), 6.08 (d, 1H, J = 10 
Hz), 5.81 (dd, 1H, J = 10, 4.5 Hz), 5.33 and 4.98 (ABq, 2H, J = 14 Hz),  5.17 (s, 2H), 4.88 (d, 
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1H, J = 5 Hz), 3.79 (s, 3H), 3.67 and 3.62 (ABq, 2H, J = 9 Hz), 3.44 and 3.42 (ABq, 2H, J = 18 
Hz), 3.10 (q, 4H, J = 7 Hz), 1.05 (m, 6H, J = 7 Hz). 
13C NMR: (125 MHz, CDCl3): δ 171.1, 164.6, 161.2, 159.9, 133.6, 130.7, 129.4, 129.2, 127.8, 
126.7, 126.4, 125.5, 114.0, 72.0, 68.1, 59.2, 57.5, 55.2, 48.4, 43.3, 26.0, 11.5. 
FTIR: (cm-1, Neat) 3287, 3031, 2967, 2920, 2854, 1894, 1730, 1717, 1531, 1374, 1350, 1258, 
1157, 1076, 1057, 915. 
[α]D: (c= 1.0, CHCl3) = -12.69 
MP: 123-123.4 oC 
ESI-MS (m/z): Calculated: 584.22[M + H]+ C28H34N5O7S, Found 584.51. 
 




 PMB protected-DEA-C3D 4 (60 mg, 0.1 mmol) was stirred with TFA (0.8 mL) in 
molten phenol (3 g) at 45 oC in a dry flask for 1-1.5 hours under argon. Reaction progress was 
monitored by reverse-phase TLC analysis (30% acetonitrile in water). Upon completion, the 
crude product was precipitated out of solution by adding petroleum spirit (30-40 mL) and 
placed on ice for 2 hours. The mixture was centrifuged at 3500 g for 5 minutes causing the 
precipitate to form a tight cake. The solvent was decanted, and the cake washed twice with 
petroleum spirit using vortex/centrifugation cycles. The precipitate was redissolved in 1-2 mL 
DMSO and purified using C18-reverse phase silica gel column chromatography (0-30% 




were pooled and freeze-dried overnight to give DEA-C3D 1 (23 mg, 48%) as a fluffy white 
powder. The compound was stored in the freezer in a dry flask wrapped in foil under argon. 
1H NMR: (500 MHz, CD3OD): δ 7.35-7.26 (m, 5H), 5.75 (d, 1H, J = 4.8, Hz), 5.36 and 5.07 
(ABq, 2H, J = 12.9 Hz), 5.05 (d, 1H, J= 4.8 Hz), 5.03 (m, 1H), 3.68-3.45 (m, 4H), 3.19 (q, 4H, 
J = 7.0 Hz), 1.07 (t, 6H, J = 7.0 Hz). 
13C NMR: (125 MHz, DMSO-d6): δ 171.4, 165.5, 161.8, 136.2, 130.7, 131.0, 129.5, 128.8, 
123.0, 74.6, 61.5, 59.8, 50.1, 44.0, 27.7, 12.6 
FTIR: (cm-1, Neat) 3277, 3030, 2977, 2938, 2114, 1716, 1660, 1532, 1495, 1380, 1339, 1229, 
1176, 1073, 1055, 838 
[α]D: (c= 1.0, CHCl3) = -32.5 
ESI-MS (m/z) Calculated: 464.16 (C20H26N5O6S) [M + H]
+, Found 464.21 
MP: 81.8-83.7 oC 
 
6.5.4 Amperometric measurements of nitric oxide release 
Nitric oxide was detected amperometrically using a TBR 4100 free radical analyser 
(World Precision Instruments) with an ISO-NOP microsensor probe. The probe was first 
polarised, and the baseline stabilised by placing in a stirring solution of distilled water (200 
mL) in a room temperature water bath for 12 hours. The probe was calibrated using a saturated 
solution of NO generated by bubbling the pure gas through water according to the 
manufacturer’s protocol. The saturated aqueous NO solution (1.91 mM) was diluted 1:10 to 
give a 191 µM stock solution. Aliquots of 100 µL, 200 µL, 400 µL, 800 µL and 1600 µL of 
the 191 µM stock solution were injected sequentially after stabilisation of the NO signal. A 
standard curve was generated and used to measure NO concentrations produced from cleavage 
of DEA-C3D 1 by the β-lactamases. 
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The probe was placed in PBS (20 mL, 10 mM Na2HPO4, 137 mM NaCl, 1.8 mM 
KH2PO4, 2.7 mM KCl) and stirred at room temperature to stabilise the baseline. The NO signal 
was recorded for 15 minutes or until a stable baseline was evident and DEA-C3D 1 (2 mg) was 
added to the stirring solution. Aliquots of TEM-1 β-lactamase (30 U) were added and the NO 
signal changes recorded over 1- 1.5 hour. The analogous experiment was performed using the 
TEM-1 β-lactamase-sulfo-SMCC-Fab′ 528 conjugate. Experimental data were processed and 
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Appendix 2: DNA sequences for the three designed constructs of TEM-1 β-lactamase. 
 
 
Appendix 3: Standard curve for nitrocefin assay. 
 
 






































Appendix 6: Mass spectrum of 1:10 mole ratio reaction of TEM-1 β-lactamase: sulfo-SMCC. 
 
